<?xml version="1.0" encoding="UTF-8"?><GuidelineDocument xmlns="http://gem.yale.edu" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://gem.yale.edu gemschemaiii.xsd">

<Identity id="1" source="nd">

<GuidelineTitle id="1" source="inferred">Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.</GuidelineTitle>

<Citation id="1" source="inferred">Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE Jr, Scarpero HM, Tessier CD, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. Linthicum (MD): American Urological Association (AUA); 2012 May. 36 p. [222 references]<GuidelineLength id="1" source="nd"/>

</Citation>

<GEMCutHistory id="1" source="nd">

<GEMCutVersion id="1" source="inferred">1<GEMCutAuthor id="1" source="inferred"/>

<GEMCutDate id="1" source="inferred">January 2013</GEMCutDate>

</GEMCutVersion>

</GEMCutHistory>

<ReleaseDate id="1" source="inferred">2012</ReleaseDate>

<Availability id="1" source="nd">

<Electronic id="1" source="nd"/>

<Print id="1" source="nd"/>

<Contact id="1" source="nd"/>

</Availability>

<Status id="1" source="nd"/>

<CompanionDocument id="1" source="nd">

<PatientResource id="1" source="nd"/>

<QuickReferenceGuide id="1" source="nd"/>

<TechnicalReport id="1" source="nd"/>

</CompanionDocument>

<Adaptation id="1" source="nd"/>

<StructuredAbstract id="1" source="nd"/>

</Identity>

<Developer id="1" source="nd">

<DeveloperName id="1" source="explicit">American Urological Association (AUA)</DeveloperName>

<CommitteeName id="1" source="nd">

<CommitteeExpertise id="1" source="nd"/>

<CommitteeMember id="1" source="nd">

<MemberExpertise id="1" source="nd"/>

<MemberConflict id="1" source="nd"/>

<MemberRole id="1" source="nd"/>

</CommitteeMember>

</CommitteeName>

<Funding id="1" source="nd"/>

<Endorser id="1" source="nd"/>

<ComparableGuideline id="1" source="nd"/>

<RoleOfSponsor id="1" source="nd"/>

<ConflictOfInterest id="1" source="nd">

<COIPolicy id="1" source="nd"/>

<COIDisclosure id="1" source="nd"/>

</ConflictOfInterest>

</Developer>

<Purpose id="1" source="nd">

<MainFocus id="1" source="nd"/>

<Rationale id="1" source="nd"/>

<Objective id="1" source="inferred">To provide direction to clinicians and patients regarding how to recognize non-neurogenic overactive bladder (OAB), conduct a valid diagnostic process and approach treatment with the goals of maximizing symptom control and patient quality of life while minimizing adverse events and patient burden.</Objective>

<AvailableOption id="1" source="nd"/>

<HealthOutcome id="1" source="nd"/>

<Exception id="1" source="nd"/>

</Purpose>

<IntendedAudience id="1" source="nd">

<Users id="1" source="inferred">all types of providers who evaluate and treat OAB patients, including those in general practice as well as those who specialize in various branches of medicine</Users>

<CareSetting id="1" source="nd"/>

</IntendedAudience>

<MethodOfDevelopment id="1" source="nd">

<DescriptionEvidenceCollection id="1" source="nd">

<EvidenceTimePeriod id="1" source="nd"/>

<NumberSourceDocuments id="1" source="nd"/>

<EvidenceSelectionCriteria id="1" source="nd"/>

</DescriptionEvidenceCollection>

<DescriptionEvidenceCombination id="1" source="nd"/>

<CostAnalysis id="1" source="nd"/>

<SpecificationHarmBenefit id="1" source="nd"/>

<QuantificationHarmBenefit id="1" source="nd"/>

<RoleValueJudgment id="1" source="nd"/>

<RolePatientPreference id="1" source="nd"/>

<QualifyingStatement id="1" source="nd"/>

<MethodsToReachJudgment id="1" source="nd"/>

<RatingScheme id="1" source="nd">

<EvidenceQualityRatingScheme id="1" source="inferred">AUA categorizes evidence strength as Grade A (well-conducted RCTs or exceptionally strong observational studies), Grade B (RCTs with some weaknesses of procedure or generalizability or generally strong observational studies) or Grade C (observational studies that are inconsistent, have small sample sizes or have other problems that potentially confound interpretation of data).</EvidenceQualityRatingScheme>

<RecommendationStrengthRatingScheme id="1" source="inferred">STANDARDS are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken based on Grade A or Grade B evidence. RECOMMENDATIONS are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken based on Grade C evidence. OPTIONS are non-directive statements that leave the decision to take an action up to the individual clinician and patient because the balance between benefits and risks/burdens appears relatively equal or unclear; Options may be supported by Grade A, B or C evidence. OPTIONS generally reflect the Panel’s judgment that a particular decision is best made by the clinician who knows the patient with full consideration of the patient’s prior treatment history, current quality of life, preferences and values.</RecommendationStrengthRatingScheme>

</RatingScheme>

<PatientAndPublicInvolvement id="1" source="nd"/>

</MethodOfDevelopment>

<TargetPopulation id="1" source="nd">

<Eligibility id="1" source="nd">

<InclusionCriterion id="1" source="inferred">non-neurogenic OAB<InclusionCriterionCode id="1" source="nd"/>

</InclusionCriterion>

<ExclusionCriterion id="1" source="inferred">individuals with symptoms related to neurologic conditions<ExclusionCriterionCode id="1" source="nd"/>

</ExclusionCriterion>

</Eligibility>

</TargetPopulation>

<KnowledgeComponents id="1" source="nd">

<Recommendation id="1" source="inferred">1 - Diagnosis<StatementOfFact id="1" source="nd"/>

<Conditional id="1" source="inferred">The clinician should engage in a diagnostic process to document symptoms and signs that characterize OAB and exclude other disorders that could be the cause of the patient’s symptoms; the minimum requirements for this process are a careful history, physical exam and urinalysis.<BenefitHarmAssessment id="1" source="nd"/>

<DecisionVariable id="1" source="inferred">{suspected} OAB<Value id="1" source="inferred">true</Value>

<DecisionVariableCode id="1" source="nd"/>

<DecisionVariableDescription id="1" source="nd">

<IntentionalVagueness id="1" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="1" source="nd">

<Sensitivity id="1" source="nd"/>

<Specificity id="1" source="nd"/>

<PredictiveValue id="1" source="nd"/>

</TestParameter>

<DecisionVariableCost id="1" source="nd"/>

</DecisionVariable>

<Action id="1" source="inferred">The clinician should engage in a diagnostic process to document symptoms and signs that characterize OAB and exclude other disorders that could be the cause of the patient’s symptoms; the minimum requirements for this process are a careful history, physical exam and urinalysis.<ActionActor id="1" source="inferred">clinicians</ActionActor>

<ActionCode id="1" source="nd"/>

<ActionVerb id="1" source="inferred">engage</ActionVerb>

<ActionDeonticTerm id="1" source="inferred">should</ActionDeonticTerm>

<ActionVerbComplement id="1" source="inferred">in a diagnostic process to document symptoms and signs that characterize OAB and exclude other disorders that could be the cause of the patient’s symptoms.</ActionVerbComplement>

<ActionBenefit id="1" source="nd"/>

<ActionRiskHarm id="1" source="nd"/>

<ActionDescription id="1" source="inferred">HISTORY: The clinician should carefully elicit the patient’s bladder symptoms to document duration of symptoms and baseline symptom levels, to ensure that symptoms are not the consequence of some other condition and to determine whether the patient constitutes a complex OAB presentation that may require referral. Questions should assess bladder storage symptoms associated with OAB (e.g., urgency, urgency incontinence, frequency, nocturia), other bladder storage problems (e.g., stress incontinence episodes) and bladder emptying (e.g., hesitancy, straining to void, prior history of urinary retention, force of stream, intermittency of stream). The symptom of urgency as defined by the ICS is the “complaint of sudden compelling desire to pass urine which is difficult to defer.” The interpretations of “sudden” and “compelling” are highly subjective and difficult to quantitate. Nevertheless, the clinician can simply ask if the patient has a problem getting to the bathroom in time, assuming the patient has normal mobility.

Bladder function is related to amount and type of fluid intake. Excessive fluid intake can produce voiding patterns that mimic OAB symptoms. For this reason, an inquiry into fluid intake habits should be performed, including asking patients how much fluid and of what type (e.g., with or without caffeine) they drink each day, how many times they void each day and how many times they void at night. Patients who do not appear able to provide accurate intake and voiding information should fill out a fluid diary. Urinary frequency varies across individuals. In community-dwelling healthy adults, normal frequency consists of voiding every three to four hours with a median of approximately six voids a day. Current medication use also should be reviewed to ensure that voiding symptoms are not a consequence of a prescribed medication, particularly diuretics.

The degree of bother from bladder symptoms also should be assessed. If a patient is not significantly bothered by his/her bladder symptoms, then there would be less compelling reason to treat the symptoms. Degree of bother can affect different domains of daily activities related to work and leisure. Patients may avoid certain activities (e.g., travel, situations that do not allow easy access to a toilet) because of their bladder symptoms.

Co-morbid conditions should be completely elicited as these conditions may directly impact bladder function. Patients with co-morbid conditions and OAB symptoms would be considered complicated OAB patients. These co-morbid conditions include neurologic diseases (i.e., stroke, multiple sclerosis, spinal cord injury), mobility deficits, medically complicated/uncontrolled diabetes, fecal motility disorders (fecal incontinence/constipation), chronic pelvic pain, history of recurrent urinary tract infections (UTIs), gross hematuria, prior pelvic/vaginal surgeries (incontinence/prolapse surgeries), pelvic cancer (bladder, colon, cervix, uterus, prostate) and pelvic radiation. The female patient with significant prolapse (i.e., prolapse beyond the introitus) also may be considered a complicated OAB patient. Patients with urgency incontinence, particularly younger patients, or a patient with extremely severe symptoms could represent a complicated OAB patient with an occult neurologic condition. A patient who has failed multiple anti-muscarinics to control OAB symptoms could also be considered a complicated OAB patient. If the history elicits any of these co-morbid conditions and/or special situations, then the clinician should consider referring these patients to a specialist for further evaluation and treatment.<IntentionalVagueness id="1" source="nd"/>

</ActionDescription>

<ActionDescription id="38" source="inferred">PHYSICAL EXAMINATION: A careful, directed physical exam should be performed. An abdominal exam should be performed to assess for scars, masses, hernias and areas of tenderness as well as for suprapubic distension that may indicate urinary retention. Examination of lower extremities for edema should be done to give the clinician an assessment of the potential for fluid shifts during periods of postural changes. A rectal/genitourinary exam to rule out pelvic floor disorders (e.g., pelvic floor muscle spasticity, pain, pelvic organ prolapse) in females and prostatic pathology in males should be performed. In menopausal females, atrophic vaginitis should be assessed as a possible contributing factor to incontinence symptoms. The examiner should assess for perineal skin for rash or breakdown. The examiner also should assess perineal sensation, rectal sphincter tone and ability to contract the anal sphincter in order to evaluate pelvic floor tone and potential ability to perform pelvic floor exercises (e.g., the ability to contract the levator ani muscles) as well as to rule out impaction and constipation.

Cognitive impairment is related to symptom severity and has therapeutic implications regarding goals and options. The Mini-Mental State Examination (MMSE) is a standardized, quick and useful assessment of cognitive function. An MMSE should be conducted on all patients who may be at risk for cognitive impairment to determine whether symptoms are aggravated by cognitive problems, to ensure that they will be able to follow directions for behavioral therapy and/or to determine the degree of risk for cognitive decline with anti-muscarinic therapy. In the Panel’s experience, the ability of the patient to dress independently is informative of sufficient motor skills related to toileting habits.<IntentionalVagueness id="114" source="nd"/>

</ActionDescription>

<ActionDescription id="39" source="inferred">URINALYSIS: A urinalysis to rule out UTI and hematuria should be performed. A urine culture is not necessary unless indication of infection (i.e., nitrites/leukocyte esterase on dipstick, pyuria/bacteriuria on microscopic exam) is found and may be done at the discretion of the clinician. If evidence of infection is detected, then a culture should be performed, the infection treated appropriately and the patient should be queried regarding symptoms once the infection has cleared. If evidence of hematuria not associated with infection is found, then the patient should be referred for urologic evaluation.<IntentionalVagueness id="115" source="nd"/>

</ActionDescription>

<ActionCost id="1" source="nd"/>

<ActionValue id="1" source="nd"/>

<ActionType id="1" source="nd"/>

</Action>

<Reason id="1" source="nd"/>

<EvidenceQuality id="1" source="nd">

<EvidenceQualityDescription id="1" source="nd"/>

<Disagreement id="1" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="1" source="inferred">Clinical Principle<RecommendationStrengthCode id="1" source="nd"/>

</RecommendationStrength>

<Flexibility id="1" source="nd"/>

<Logic id="1" source="inferred">If &#13;

{suspected} OAB is [true] &#13;

Then &#13;

The clinician should engage in a diagnostic process to document symptoms and signs that characterize OAB and exclude other disorders that could be the cause of the patient’s symptoms; the minimum requirements for this process are a careful history, physical exam and urinalysis.</Logic>

<Cost id="1" source="nd"/>

<Linkage id="1" source="nd"/>

<Reference id="1" source="nd"/>

<Certainty id="1" source="nd"/>

<Goal id="1" source="nd"/>

</Conditional>

<Imperative id="1" source="inferred">

<BenefitHarmAssessment id="1" source="nd"/>

<Scope id="1" source="nd">

<ScopeCode id="1" source="nd"/>

</Scope>

<Directive id="1" source="nd">

<DirectiveActor id="1" source="nd"/>

<DirectiveCode id="1" source="nd"/>

<DirectiveVerb id="1" source="nd"/>

<DirectiveDeonticTerm id="1" source="nd"/>

<DirectiveVerbComplement id="1" source="nd"/>

<DirectiveBenefit id="1" source="nd"/>

<DirectiveRiskHarm id="1" source="nd"/>

<DirectiveDescription id="1" source="nd">

<IntentionalVagueness id="1" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="1" source="nd"/>

<DirectiveValue id="1" source="nd"/>

<DirectiveType id="1" source="nd"/>

</Directive>

<Reason id="1" source="nd"/>

<EvidenceQuality id="1" source="nd">

<EvidenceQualityDescription id="1" source="nd"/>

<Disagreement id="1" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="1" source="inferred">

<RecommendationStrengthCode id="1" source="nd"/>

</RecommendationStrength>

<Flexibility id="1" source="nd"/>

<Logic id="1" source="nd"/>

<Cost id="1" source="nd"/>

<Linkage id="1" source="nd"/>

<Reference id="1" source="nd"/>

<Certainty id="1" source="nd"/>

<Goal id="1" source="nd"/>

</Imperative>

<RecommendationNotes id="1" source="nd"/>

</Recommendation>

<Recommendation id="1" source="inferred">2 - Diagnosis<StatementOfFact id="1" source="nd"/>

<Conditional id="1" source="inferred">In some patients, additional procedures and measures may be necessary to validate an OAB diagnosis, exclude other disorders and fully inform the treatment plan. At the clinician’s discretion, a urine culture and/or post-void residual assessment may be performed and information from bladder diaries and/or symptom questionnaires may be obtained.<BenefitHarmAssessment id="1" source="nd"/>

<DecisionVariable id="1" source="inferred">selected patients with OAB<Value id="1" source="nd"/>

<DecisionVariableCode id="1" source="nd"/>

<DecisionVariableDescription id="1" source="inferred">

<IntentionalVagueness id="1" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="1" source="nd">

<Sensitivity id="1" source="nd"/>

<Specificity id="1" source="nd"/>

<PredictiveValue id="1" source="nd"/>

</TestParameter>

<DecisionVariableCost id="1" source="nd"/>

</DecisionVariable>

<Action id="1" source="inferred">at the clinician's discretion, a urine culture may be performed<ActionActor id="1" source="inferred">clinicians</ActionActor>

<ActionCode id="1" source="nd"/>

<ActionVerb id="1" source="inferred">perform</ActionVerb>

<ActionDeonticTerm id="1" source="inferred">may</ActionDeonticTerm>

<ActionVerbComplement id="1" source="inferred">a urine culture</ActionVerbComplement>

<ActionBenefit id="1" source="nd"/>

<ActionRiskHarm id="1" source="nd"/>

<ActionDescription id="45" source="inferred">URINE CULTURE: Urinalysis is unreliable for identification of bacterial counts below 100,000cfu/ml. In some patients with irritative voiding symptoms but without overt signs of infection, a urine culture may be appropriate to completely exclude the presence of clinically significant bacteriuria<IntentionalVagueness id="121" source="nd"/>

</ActionDescription>

<ActionCost id="1" source="nd"/>

<ActionValue id="1" source="nd"/>

<ActionType id="1" source="nd"/>

</Action>

<Action id="34" source="inferred">at the clinician's discretion, a post-void residual assessment may be performed<ActionActor id="34" source="inferred">clinicians</ActionActor>

<ActionCode codeset="" id="34" source="nd"/>

<ActionVerb id="34" source="inferred">perform</ActionVerb>

<ActionDeonticTerm id="34" source="inferred">may</ActionDeonticTerm>

<ActionVerbComplement id="34" source="inferred">a post-void residual assessment</ActionVerbComplement>

<ActionBenefit id="34" source="nd"/>

<ActionRiskHarm id="34" source="nd"/>

<ActionDescription id="47" source="inferred">POST-VOID RESIDUAL (PVR): Measurement of the PVR is not necessary for patients who are receiving first-line behavioral interventions (see Guideline Statement 6 below) or for uncomplicated patients (i.e., patients without a history of or risk factors for urinary retention) receiving anti-muscarinic medications. Because anti-muscarinic medications can induce urinary retention, particularly in complicated patients with retention risk factors, PVR should be assessed in patients with obstructive symptoms, history of incontinence or prostatic surgery, neurologic diagnoses and in other patients at clinician discretion when PVR assessment is deemed necessary to optimize care and minimize potential risks. It should be noted, however, that the occurrence of symptomatic urinary retention or asymptomatic elevations of postvoid residuals after the addition of anti-muscarinic agents occurs in a small proportion of patients; previously undiagnosed poor detrusor function may be unmasked in those individuals.

PVR should be measured with an ultrasound bladder scanner immediately after the patient voids. If an ultrasound scanner is not available, then urethral catheterization may be used to assess PVR. For any patient on anti-muscarinic therapy, the clinician should be prepared to monitor PVR during the course of treatment should obstructive voiding symptoms appear. As there is considerable overlap between storage and emptying voiding symptoms, baseline PVRs should be performed for men with symptoms prior to initiation of anti-muscarinic therapy. Anti-muscarinics should be used with caution in patients with PVR &gt;250-300 mL. Most randomized trials that evaluated anti-muscarinics for OAB treatment used a PVR of 150-200 mL as an exclusion criterion; the overwhelming majority of participants in these trials were women.<IntentionalVagueness id="123" source="nd"/>

</ActionDescription>

<ActionCost id="34" source="nd"/>

<ActionValue id="34" source="nd"/>

<ActionType id="34" source="nd"/>

</Action>

<Action id="33" source="inferred">at the clinician's discretion, information from bladder diaries may be obtained.<ActionActor id="33" source="inferred">clinicians</ActionActor>

<ActionCode id="33" source="nd"/>

<ActionVerb id="33" source="inferred">obtain</ActionVerb>

<ActionDeonticTerm id="33" source="inferred">may</ActionDeonticTerm>

<ActionVerbComplement id="33" source="inferred">information from bladder diaries</ActionVerbComplement>

<ActionBenefit id="33" source="nd"/>

<ActionRiskHarm id="33" source="nd"/>

<ActionDescription id="43" source="inferred">BLADDER DIARIES: Diaries that document intake and voiding behavior may be useful in some patients, particularly the patient who cannot describe or who is not familiar with intake and voiding patterns. Diaries also are useful to document baseline symptom levels so that treatment efficacy may be assessed.

In particular, self-monitoring with a bladder diary for three to seven days is a useful first step in initiating behavioral treatments for OAB. At a minimum, the patient documents the time of each void and incontinence episode and the circumstances or reasons for the incontinence episode. Rating the degree of urgency associated with each void and incontinence episode also can be useful. Adding measures of voided volumes can provide a practical estimate of the patient’s functional bladder capacity in daily life and estimate the amount of overall fluid intake. Recording voided volumes also can be useful to differentiate between polyuria (characterized by normal or large volume voids) from OAB (characterized by frequent small voids). It is more burdensome, however, and is usually completed for only 24 to 48 hours.

The bladder diary is a useful tool for both the clinician and the patient. In the evaluation phase, it provides information that can help the clinician plan appropriate components of intervention, particularly behavioral intervention. Recording the times that the patient voids provides a foundation for determining voiding intervals in bladder training programs. During the course of treatment, it can be used to monitor symptoms to track the efficacy of various treatment components and guide the intervention. For the patient, the self-monitoring effect of completing the diary enhances awareness of voiding habits and helps them recognize activities that can trigger incontinence. Twenty-four hour pad weights also can provide useful information regarding the severity of incontinence symptoms.<IntentionalVagueness id="119" source="nd"/>

</ActionDescription>

<ActionCost id="33" source="nd"/>

<ActionValue id="33" source="nd"/>

<ActionType id="33" source="nd"/>

</Action>

<Action id="35" source="inferred">at the clinician's discretion, information from symptom questionnaires may be obtained.<ActionActor id="35" source="inferred">clinicians</ActionActor>

<ActionCode id="35" source="nd"/>

<ActionVerb id="35" source="inferred">obtain</ActionVerb>

<ActionDeonticTerm id="35" source="inferred">may</ActionDeonticTerm>

<ActionVerbComplement id="35" source="inferred">information from symptom questionnaires</ActionVerbComplement>

<ActionBenefit id="35" source="nd"/>

<ActionRiskHarm id="35" source="nd"/>

<ActionDescription id="48" source="inferred">SYMPTOM QUESTIONNAIRES: Validated symptom questionnaires have been utilized in OAB clinical trials to quantitate bladder symptom and bother changes with OAB therapies. Among these questionnaires are the Urogenital Distress Inventory (UDI), the UDI-6 Short Form, the Incontinence Impact Questionnaire (II-Q) and the Overactive Bladder Questionnaire (OAB-q). The rationale for utilization of these validated questionnaires is to quantitate and follow the patients’ responses to OAB treatment as well as to obtain baseline and post-treatment levels of bother.<IntentionalVagueness id="124" source="nd"/>

</ActionDescription>

<ActionCost id="35" source="nd"/>

<ActionValue id="35" source="nd"/>

<ActionType id="35" source="nd"/>

</Action>

<Reason id="1" source="inferred">In some patients, additional procedures and measures may be necessary to validate an OAB diagnosis, exclude other disorders and fully inform the treatment plan.</Reason>

<EvidenceQuality id="1" source="nd">

<EvidenceQualityDescription id="1" source="nd"/>

<Disagreement id="1" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="1" source="inferred">Clinical Principle<RecommendationStrengthCode id="1" source="nd"/>

</RecommendationStrength>

<Flexibility id="1" source="nd"/>

<Logic id="1" source="inferred">If &#13;

selected patients with OAB&#13;

Then &#13;

(at the clinician's discretion, a urine culture may be performed&#13;

OR&#13;

at the clinician's discretion, a post-void residual assessment may be performed) &#13;

AND &#13;&#13;

(at the clinician's discretion, information from bladder diaries may be obtained.&#13;

OR&#13;

at the clinician's discretion, information from symptom questionnaires may be obtained.)</Logic>

<Cost id="1" source="nd"/>

<Linkage id="1" source="nd"/>

<Reference id="1" source="nd"/>

<Certainty id="1" source="nd"/>

<Goal id="1" source="nd"/>

</Conditional>

<Imperative id="1" source="inferred">

<BenefitHarmAssessment id="2" source="nd"/>

<Scope id="1" source="nd">

<ScopeCode id="1" source="nd"/>

</Scope>

<Directive id="1" source="nd">

<DirectiveActor id="1" source="nd"/>

<DirectiveCode id="1" source="nd"/>

<DirectiveVerb id="1" source="nd"/>

<DirectiveDeonticTerm id="1" source="nd"/>

<DirectiveVerbComplement id="1" source="nd"/>

<DirectiveBenefit id="1" source="nd"/>

<DirectiveRiskHarm id="1" source="nd"/>

<DirectiveDescription id="1" source="nd">

<IntentionalVagueness id="3" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="1" source="nd"/>

<DirectiveValue id="1" source="nd"/>

<DirectiveType id="1" source="nd"/>

</Directive>

<Reason id="2" source="nd"/>

<EvidenceQuality id="2" source="nd">

<EvidenceQualityDescription id="2" source="nd"/>

<Disagreement id="2" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="2" source="inferred">

<RecommendationStrengthCode id="2" source="nd"/>

</RecommendationStrength>

<Flexibility id="2" source="nd"/>

<Logic id="2" source="nd"/>

<Cost id="2" source="nd"/>

<Linkage id="2" source="nd"/>

<Reference id="2" source="nd"/>

<Certainty id="2" source="nd"/>

<Goal id="2" source="nd"/>

</Imperative>

<RecommendationNotes id="1" source="nd"/>

</Recommendation>

<Recommendation id="2" source="inferred">3 - Diagnosis<StatementOfFact id="2" source="nd"/>

<Conditional id="2" source="inferred">Urodynamics, cystoscopy and diagnostic renal and bladder ultrasound should not be used in the initial workup of the uncomplicated patient.<BenefitHarmAssessment id="3" source="nd"/>

<DecisionVariable id="2" source="inferred">uncomplicated OAB patient<Value id="2" source="inferred">true</Value>

<DecisionVariableCode id="2" source="nd"/>

<DecisionVariableDescription id="2" source="inferred">patients without a history of or risk factors for urinary retention<IntentionalVagueness id="4" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="2" source="nd">

<Sensitivity id="2" source="nd"/>

<Specificity id="2" source="nd"/>

<PredictiveValue id="2" source="nd"/>

</TestParameter>

<DecisionVariableCost id="2" source="inferred"/>

</DecisionVariable>

<Action id="2" source="inferred">do not use urodynamics in the initial diagnostic workup<ActionActor id="2" source="inferred">clinicians</ActionActor>

<ActionCode id="2" source="nd"/>

<ActionVerb id="2" source="inferred">use</ActionVerb>

<ActionDeonticTerm id="2" source="inferred">should not</ActionDeonticTerm>

<ActionVerbComplement id="2" source="inferred">urodynamics in the initial diagnostic workup</ActionVerbComplement>

<ActionBenefit id="2" source="nd"/>

<ActionRiskHarm id="2" source="nd"/>

<ActionDescription id="2" source="nd">

<IntentionalVagueness id="5" source="nd"/>

</ActionDescription>

<ActionCost id="2" source="nd"/>

<ActionValue id="2" source="nd"/>

<ActionType id="2" source="nd"/>

</Action>

<Action id="3" source="inferred">do not use cystoscopy in the initial diagnostic workup<ActionActor id="3" source="inferred">clinicians</ActionActor>

<ActionCode id="3" source="nd"/>

<ActionVerb id="3" source="inferred">use</ActionVerb>

<ActionDeonticTerm id="3" source="inferred">should not</ActionDeonticTerm>

<ActionVerbComplement id="3" source="inferred">cystoscopy in the initial diagnostic workup</ActionVerbComplement>

<ActionBenefit id="3" source="nd"/>

<ActionRiskHarm id="3" source="nd"/>

<ActionDescription id="3" source="nd">

<IntentionalVagueness id="7" source="nd"/>

</ActionDescription>

<ActionCost id="3" source="nd"/>

<ActionValue id="3" source="nd"/>

<ActionType id="3" source="nd"/>

</Action>

<Action id="4" source="inferred">do not use diagnostic renal and bladder ultrasound in the initial diagnostic workup<ActionActor id="4" source="inferred">clinicians</ActionActor>

<ActionCode id="4" source="nd"/>

<ActionVerb id="4" source="inferred">use</ActionVerb>

<ActionDeonticTerm id="4" source="inferred">should not</ActionDeonticTerm>

<ActionVerbComplement id="4" source="inferred">diagnostic renal and bladder ultrasound in the initial diagnostic workup</ActionVerbComplement>

<ActionBenefit id="4" source="nd"/>

<ActionRiskHarm id="4" source="nd"/>

<ActionDescription id="4" source="nd">

<IntentionalVagueness id="8" source="nd"/>

</ActionDescription>

<ActionCost id="4" source="nd"/>

<ActionValue id="4" source="nd"/>

<ActionType id="4" source="nd"/>

</Action>

<Reason id="3" source="inferred">Urodynamics, cystoscopy and diagnostic renal and bladder ultrasound are not recommended in the initial diagnostic workup of the uncomplicated OAB patient. For complicated patients or refractory patients who have failed multiple OAB treatments, the choice of additional diagnostic tests depends on patient history and presentation and clinician judgment. In some cases, additional information may make clear that the patient has neurogenic OAB rather than non-neurogenic OAB and requires a different treatment plan. Patients with hematuria should be referred for a urologic work up. In the low-risk uncomplicated patient without microscopic hematuria, urine cytology is infrequently associated with atypia requiring further investigation, engendering costs and possibly resulting in morbidity. Urine cytology is not recommended in the routine evaluation of patients with uncomplicated OAB without hematuria who respond to therapy.</Reason>

<EvidenceQuality id="3" source="nd">

<EvidenceQualityDescription id="3" source="nd"/>

<Disagreement id="3" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="3" source="inferred">Clinical Principle<RecommendationStrengthCode id="3" source="nd"/>

</RecommendationStrength>

<Flexibility id="3" source="nd"/>

<Logic id="3" source="inferred">If &#13;

uncomplicated OAB patient is [true] &#13;

Then &#13;

do not use urodynamics in the initial diagnostic workup&#13;

AND&#13;

do not use cystoscopy in the initial diagnostic workup&#13;

AND&#13;

do not use diagnostic renal and bladder ultrasound in the initial diagnostic workup</Logic>

<Cost id="3" source="nd"/>

<Linkage id="3" source="nd"/>

<Reference id="3" source="nd"/>

<Certainty id="3" source="nd"/>

<Goal id="3" source="nd"/>

</Conditional>

<Imperative id="2" source="nd">

<BenefitHarmAssessment id="4" source="nd"/>

<Scope id="2" source="nd">

<ScopeCode id="2" source="nd"/>

</Scope>

<Directive id="2" source="nd">

<DirectiveActor id="2" source="nd"/>

<DirectiveCode id="2" source="nd"/>

<DirectiveVerb id="2" source="nd"/>

<DirectiveDeonticTerm id="2" source="nd"/>

<DirectiveVerbComplement id="2" source="nd"/>

<DirectiveBenefit id="2" source="nd"/>

<DirectiveRiskHarm id="2" source="nd"/>

<DirectiveDescription id="2" source="nd">

<IntentionalVagueness id="6" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="2" source="nd"/>

<DirectiveValue id="2" source="nd"/>

<DirectiveType id="2" source="nd"/>

</Directive>

<Reason id="4" source="nd"/>

<EvidenceQuality id="4" source="nd">

<EvidenceQualityDescription id="4" source="nd"/>

<Disagreement id="4" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="4" source="nd">

<RecommendationStrengthCode id="4" source="nd"/>

</RecommendationStrength>

<Flexibility id="4" source="nd"/>

<Logic id="4" source="nd"/>

<Cost id="4" source="nd"/>

<Linkage id="4" source="nd"/>

<Reference id="4" source="nd"/>

<Certainty id="4" source="nd"/>

<Goal id="4" source="nd"/>

</Imperative>

<RecommendationNotes id="2" source="nd"/>

</Recommendation>

<Recommendation id="3" source="inferred">4 - Treatment<StatementOfFact id="3" source="nd"/>

<Conditional id="3" source="inferred">OAB is not a disease; it is a symptom complex that generally is not a life threatening condition. After assessment has been performed to exclude conditions requiring treatment and counseling, no treatment is an acceptable choice made by some patients and caregivers.<BenefitHarmAssessment id="5" source="nd"/>

<DecisionVariable id="3" source="inferred">OAB<Value id="3" source="inferred">true</Value>

<DecisionVariableCode id="3" source="nd"/>

<DecisionVariableDescription id="3" source="nd">

<IntentionalVagueness id="9" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="3" source="nd">

<Sensitivity id="3" source="nd"/>

<Specificity id="3" source="nd"/>

<PredictiveValue id="3" source="nd"/>

</TestParameter>

<DecisionVariableCost id="3" source="nd"/>

</DecisionVariable>

<DecisionVariable id="4" source="inferred">assessment has been performed to exclude conditions requiring treatment and counseling<Value id="4" source="inferred">true</Value>

<DecisionVariableCode id="4" source="nd"/>

<DecisionVariableDescription id="4" source="nd">

<IntentionalVagueness id="12" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="4" source="nd">

<Sensitivity id="4" source="nd"/>

<Specificity id="4" source="nd"/>

<PredictiveValue id="4" source="nd"/>

</TestParameter>

<DecisionVariableCost id="4" source="nd"/>

</DecisionVariable>

<Action id="5" source="inferred">no treatment is an acceptable choice made by some patients and caregivers<ActionActor id="5" source="nd"/>

<ActionCode id="5" source="nd"/>

<ActionVerb id="5" source="nd"/>

<ActionDeonticTerm id="5" source="nd"/>

<ActionVerbComplement id="5" source="nd"/>

<ActionBenefit id="5" source="nd"/>

<ActionRiskHarm id="5" source="nd"/>

<ActionDescription id="5" source="nd">

<IntentionalVagueness id="10" source="nd"/>

</ActionDescription>

<ActionCost id="5" source="nd"/>

<ActionValue id="5" source="nd"/>

<ActionType id="5" source="nd"/>

</Action>

<Reason id="5" source="inferred">OAB is not a disease; it is a symptom complex that generally is not a life threatening condition.</Reason>

<Reason id="7" source="inferred">Initiating treatment for OAB generally presumes that the patient can perceive an improvement in his or her quality of life. In patients who cannot perceive symptom improvements, treatment may not be appropriate, may be potentially unsafe or may be futile (e.g., in the very elderly or demented patient) except in patients for whom OAB symptoms present a significant health risk (e.g., risk for skin breakdown). It is important for clinicians who treat this problem to recognize this issue and to set feasible therapeutic goals with the patient and/or caregiver. The presence of an overactive bladder frequently accompanies other disorders such as deficiencies in cognition (i.e., dementia) and/or poor mobility, which can complicate treatment. To treat incontinence, optimally the patient must have a desire to be continent or have a desire for symptom improvement. In patients with cognitive deficits, this desire may not be present and family and/or caregivers may have difficulty understanding that simply giving a medication will not correct the problem. The other common situation associated with OAB is severely reduced mobility. Causes can range from dementia, severe arthritis, severe obesity, hemiparesis/plegia, and lower extremity amputations. In these situations, despite receiving an urge to urinate, the patient physically cannot get from their current position without assistance to a toileting facility. This cannot be corrected pharmacologically and should be recognized by the treating physician.

In certain patients for whom hygiene and skin breakdown are major concerns, treatment may be considered regardless of the patient’s perceptions when it is in the patient’s best interests. In these patients, behavioral strategies that include prompted voiding and fluid management may be helpful. Pharmacologic treatments and invasive treatments, however, are generally not appropriate for these individuals. The Panel also recognizes that untreated incontinence can result in falls when a patient with compromised mobility attempts to move quickly to a toileting facility. The treating physician, the patient and the caregiver must weigh these risks when making the decision whether and how to treat OAB.</Reason>

<EvidenceQuality id="5" source="inferred">

<EvidenceQualityDescription id="5" source="nd"/>

<Disagreement id="5" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="5" source="inferred">Expert Opinion<RecommendationStrengthCode id="5" source="nd"/>

</RecommendationStrength>

<Flexibility id="5" source="nd"/>

<Logic id="5" source="inferred">If &#13;

OAB is [true] &#13;&#13;

AND&#13;&#13;

assessment has been performed to exclude conditions requiring treatment and counseling is [true] &#13;

Then &#13;

no treatment is an acceptable choice made by some patients and caregivers</Logic>

<Cost id="5" source="nd"/>

<Linkage id="5" source="nd"/>

<Reference id="5" source="nd"/>

<Certainty id="5" source="nd"/>

<Goal id="5" source="nd"/>

</Conditional>

<Imperative id="3" source="nd">

<BenefitHarmAssessment id="6" source="nd"/>

<Scope id="3" source="nd">

<ScopeCode id="3" source="nd"/>

</Scope>

<Directive id="3" source="nd">

<DirectiveActor id="3" source="nd"/>

<DirectiveCode id="3" source="nd"/>

<DirectiveVerb id="3" source="nd"/>

<DirectiveDeonticTerm id="3" source="nd"/>

<DirectiveVerbComplement id="3" source="nd"/>

<DirectiveBenefit id="3" source="nd"/>

<DirectiveRiskHarm id="3" source="nd"/>

<DirectiveDescription id="3" source="nd">

<IntentionalVagueness id="11" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="3" source="nd"/>

<DirectiveValue id="3" source="nd"/>

<DirectiveType id="3" source="nd"/>

</Directive>

<Reason id="6" source="nd"/>

<EvidenceQuality id="6" source="nd">

<EvidenceQualityDescription id="6" source="nd"/>

<Disagreement id="6" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="6" source="nd">

<RecommendationStrengthCode id="6" source="nd"/>

</RecommendationStrength>

<Flexibility id="6" source="nd"/>

<Logic id="6" source="nd"/>

<Cost id="6" source="nd"/>

<Linkage id="6" source="nd"/>

<Reference id="6" source="nd"/>

<Certainty id="6" source="nd"/>

<Goal id="6" source="nd"/>

</Imperative>

<RecommendationNotes id="3" source="nd"/>

</Recommendation>

<Recommendation id="4" source="inferred">5 - Treatment<StatementOfFact id="4" source="nd"/>

<Conditional id="4" source="inferred">Clinicians should provide education to patients regarding normal lower urinary tract function, what is known about OAB, the benefits vs. risks/burdens of the available treatment alternatives and the fact that acceptable symptom control may require trials of multiple therapeutic options before it is achieved.<BenefitHarmAssessment id="7" source="nd"/>

<DecisionVariable id="5" source="inferred">OAB<Value id="5" source="inferred">true</Value>

<DecisionVariableCode id="5" source="nd"/>

<DecisionVariableDescription id="5" source="nd">

<IntentionalVagueness id="13" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="5" source="nd">

<Sensitivity id="5" source="nd"/>

<Specificity id="5" source="nd"/>

<PredictiveValue id="5" source="nd"/>

</TestParameter>

<DecisionVariableCost id="5" source="nd"/>

</DecisionVariable>

<Action id="6" source="inferred">Clinicians should provide education to patients regarding normal lower urinary tract function, what is known about OAB, the benefits vs. risks/burdens of the available treatment alternatives and the fact that acceptable symptom control may require trials of multiple therapeutic options before it is achieved.<ActionActor id="6" source="inferred">clinicians</ActionActor>

<ActionCode id="6" source="nd"/>

<ActionVerb id="6" source="inferred">provide</ActionVerb>

<ActionDeonticTerm id="6" source="inferred">should</ActionDeonticTerm>

<ActionVerbComplement id="6" source="inferred">education to patients regarding normal lower urinary tract function, what is known about OAB, the benefits vs. risks/burdens of the available treatment alternatives and the fact that acceptable symptom control may require trials of multiple therapeutic options before it is achieved.</ActionVerbComplement>

<ActionBenefit id="6" source="nd"/>

<ActionRiskHarm id="6" source="nd"/>

<ActionDescription id="6" source="inferred">Prior to initiating treatment, the clinician should provide patient education regarding normal and abnormal bladder function, including voiding frequency and toileting behavior.<IntentionalVagueness id="14" source="nd"/>

</ActionDescription>

<ActionCost id="6" source="nd"/>

<ActionValue id="6" source="nd"/>

<ActionType id="6" source="nd"/>

</Action>

<Reason id="8" source="inferred">Explaining what is normal can help the patient understand how their condition diverges from normal and gives them a comparator (or goal) for judging their own progress in treatment. Education also empowers the patient to engage and participate in their treatment, which is essential when using interventions that rely on behavior change. Patients must understand that voiding is a behavior that can be managed and that successful OAB treatment requires a willing participant who is informed and engaged in the treatment process.</Reason>

<Reason id="10" source="inferred">Patients should be informed that OAB is a symptom complex with a variable and chronic course that needs to be managed over time, that it primarily affects quality of life, that there is no single ideal treatment and that available treatments vary in the effort required from the patient as well as in invasiveness, risk of adverse events and reversibility. An effective treatment plan depends on patients having realistic goals for treatment and a clear understanding of the risks and burdens of particular treatments. In this context, it is important to understand the patient's expectations of treatment, not only in terms of its outcome, but regarding what is required of them as well. Expectations are important because they affect motivation and adherence, and they can influence the patient's interpretation of treatment effects and satisfaction with outcomes.</Reason>

<Reason id="11" source="inferred">Most OAB treatments can improve patient symptoms but not eliminate them. The available OAB treatments, with the exception of behavioral therapies, present risks for adverse events, some of which are serious. When initiating behavioral interventions, it is crucial that the patient understands that treatment progress and outcomes will depend on their active participation and persistence over time. It is also useful for them to understand several other aspects of behavioral change: progress is usually gradual, change can be irregular with good days and bad days and long-term change in symptoms depends on their long-term change in behavior.</Reason>

<Reason id="12" source="inferred">Patients may decide that the symptomatic improvement achieved with a particular therapy (e.g., from 5 incontinence episodes per day to 3 incontinence episodes per day) is not worthwhile given the adverse events associated with that treatment (e.g., dry mouth and constipation associated with anti-muscarinic therapy) and choose to discontinue therapy despite symptomatic improvement. Choosing to forego treatment is a valid decision. It is the opinion of the Panel that patients seeking treatment initially and at any point in the treatment algorithm should be told that they may opt for no treatment with minimal adverse effects on their health and no impact on the success of later management should they choose to pursue treatment in the future.</Reason>

<EvidenceQuality id="7" source="nd">

<EvidenceQualityDescription id="7" source="nd"/>

<Disagreement id="7" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="7" source="inferred">Clinical Principle<RecommendationStrengthCode id="7" source="nd"/>

</RecommendationStrength>

<Flexibility id="7" source="inferred"/>

<Logic id="7" source="inferred">If &#13;

OAB is [true] &#13;

Then &#13;

Clinicians should provide education to patients regarding normal lower urinary tract function, what is known about OAB, the benefits vs. risks/burdens of the available treatment alternatives and the fact that acceptable symptom control may require trials of multiple therapeutic options before it is achieved.</Logic>

<Cost id="7" source="nd"/>

<Linkage id="7" source="nd"/>

<Reference id="7" source="nd"/>

<Certainty id="7" source="nd"/>

<Goal id="7" source="nd"/>

</Conditional>

<Imperative id="4" source="nd">

<BenefitHarmAssessment id="8" source="nd"/>

<Scope id="4" source="nd">

<ScopeCode id="4" source="nd"/>

</Scope>

<Directive id="4" source="nd">

<DirectiveActor id="4" source="nd"/>

<DirectiveCode id="4" source="nd"/>

<DirectiveVerb id="4" source="nd"/>

<DirectiveDeonticTerm id="4" source="nd"/>

<DirectiveVerbComplement id="4" source="nd"/>

<DirectiveBenefit id="4" source="nd"/>

<DirectiveRiskHarm id="4" source="nd"/>

<DirectiveDescription id="4" source="nd">

<IntentionalVagueness id="15" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="4" source="nd"/>

<DirectiveValue id="4" source="nd"/>

<DirectiveType id="4" source="nd"/>

</Directive>

<Reason id="9" source="nd"/>

<EvidenceQuality id="8" source="nd">

<EvidenceQualityDescription id="8" source="nd"/>

<Disagreement id="8" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="8" source="nd">

<RecommendationStrengthCode id="8" source="nd"/>

</RecommendationStrength>

<Flexibility id="8" source="nd"/>

<Logic id="8" source="nd"/>

<Cost id="8" source="nd"/>

<Linkage id="8" source="nd"/>

<Reference id="8" source="nd"/>

<Certainty id="8" source="nd"/>

<Goal id="8" source="nd"/>

</Imperative>

<RecommendationNotes id="4" source="nd"/>

</Recommendation>

<Recommendation id="5" source="inferred">6 - First Line Treatments: Behavioral Therapies<StatementOfFact id="5" source="nd"/>

<Conditional id="5" source="inferred">Clinicians should offer behavioral therapies (e.g., bladder training, bladder control strategies, pelvic floor muscle training, fluid management) as first line therapy to all patients with OAB.<BenefitHarmAssessment id="9" source="nd"/>

<DecisionVariable id="7" source="inferred">OAB<Value id="7" source="inferred">true</Value>

<DecisionVariableCode id="7" source="nd"/>

<DecisionVariableDescription id="7" source="inferred">all OAB patients, including OAB patients who require a caregiver<IntentionalVagueness id="17" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="7" source="nd">

<Sensitivity id="7" source="nd"/>

<Specificity id="7" source="nd"/>

<PredictiveValue id="7" source="nd"/>

</TestParameter>

<DecisionVariableCost id="7" source="nd"/>

</DecisionVariable>

<Action id="7" source="inferred">Clinicians should offer behavioral therapies (e.g., bladder training, bladder control strategies, pelvic floor muscle training, fluid management) as first line therapy<ActionActor id="7" source="inferred">clinicians</ActionActor>

<ActionCode codeset="" id="7" source="nd"/>

<ActionVerb id="7" source="inferred">offer</ActionVerb>

<ActionDeonticTerm id="7" source="inferred">should</ActionDeonticTerm>

<ActionVerbComplement id="7" source="inferred">behavioral therapies (e.g., bladder training, bladder control strategies, pelvic floor muscle training, fluid management) as first line therapy</ActionVerbComplement>

<ActionBenefit id="7" source="nd"/>

<ActionRiskHarm id="7" source="nd"/>

<ActionDescription id="50" source="inferred">Behavioral therapies should be offered to all OAB patients, including OAB patients who require a caregiver; caregivers can be instructed in behavioral techniques in order to optimize patient symptom control (i.e., prompted voiding, timed voiding).<IntentionalVagueness id="126" source="nd"/>

</ActionDescription>

<ActionCost id="7" source="nd"/>

<ActionValue id="7" source="nd"/>

<ActionType id="7" source="nd"/>

</Action>

<Reason id="13" source="inferred">Behavioral treatments are designated as first-line treatments because they are as effective in reducing symptom levels as are anti-muscarinic medications, and they consist of many components that can be tailored to address the individual patient’s needs and capacities. In addition, they are relatively non-invasive and, in contrast to medications, are associated with virtually no adverse events. They do require the active participation of the patient and/or of the patient’s caregiver, however, as well as time and effort from the clinician.</Reason>

<Reason id="15" source="inferred">Although most patients do not experience complete symptom relief with behavioral intervention, the literature indicates that most patients experience significant reductions in symptoms and improvements in quality of life. The literature provides clear support for the effectiveness of bladder training (incremental voiding schedules done with distraction and self-assertions) and behavioral training (pelvic floor muscle training with urge suppression techniques). Typical mean improvements range from 50% to 80% reduction in the frequency of incontinence. Reductions in voiding frequency have also been documented in men and women.</Reason>

<Reason id="16" source="inferred">There is also a good body of literature addressing the effects of weight loss on incontinence specifically. The most definitive trial reported that a 6-month behavioral weight loss intervention resulted in an 8.0% weight loss in obese women, reduced overall incontinence episodes per week by 47% (compared to 28% in the control group) and reduced urgency urinary incontinence episodes by 42% (compared to 26% in controls).</Reason>

<Reason id="17" source="inferred">One study evaluated fluid management and reported that a 25% reduction in fluid intake reduced frequency and urgency. The Panel notes that when attempting intake reduction, baseline intake levels must be considered to determine whether reduction is appropriate. There is also evidence from a study of bladder training that reducing caffeine intake results in greater reductions in voiding frequency.</Reason>

<Reason id="19" source="inferred">The literature review of comparative effectiveness randomized trials indicated that various types of behavioral treatment were generally either equivalent to or superior to medications in terms of reducing incontinence episodes, improving voiding parameters such as frequency and nocturia and improving QoL.</Reason>

<Reason id="18" source="inferred">The Panel interpreted these data to indicate that behavioral therapies can result in symptomatic improvements similar to anti-muscarinics without exposing patients to adverse events. Evidence strength is Grade B because although the majority of studies were randomized trials and findings were generally consistent across studies (both randomized and observational), most of the randomized trials were of moderate quality, follow-up durations were short in most studies (12 weeks) and sample sizes were small.</Reason>

<EvidenceQuality id="9" source="inferred">Grade B; Benefits outweigh risks/burdens<EvidenceQualityDescription id="9" source="nd"/>

<Disagreement id="9" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="9" source="inferred">Standard<RecommendationStrengthCode id="9" source="nd"/>

</RecommendationStrength>

<Flexibility id="9" source="nd"/>

<Logic id="9" source="inferred">If &#13;

OAB is [true] &#13;

Then &#13;

Clinicians should offer behavioral therapies (e.g., bladder training, bladder control strategies, pelvic floor muscle training, fluid management) as first line therapy</Logic>

<Cost id="9" source="nd"/>

<Linkage id="9" source="nd"/>

<Reference id="9" source="nd"/>

<Certainty id="9" source="nd"/>

<Goal id="9" source="nd"/>

</Conditional>

<Imperative id="5" source="nd">

<BenefitHarmAssessment id="10" source="nd"/>

<Scope id="5" source="nd">

<ScopeCode id="5" source="nd"/>

</Scope>

<Directive id="5" source="nd">

<DirectiveActor id="5" source="nd"/>

<DirectiveCode id="5" source="nd"/>

<DirectiveVerb id="5" source="nd"/>

<DirectiveDeonticTerm id="5" source="nd"/>

<DirectiveVerbComplement id="5" source="nd"/>

<DirectiveBenefit id="5" source="nd"/>

<DirectiveRiskHarm id="5" source="nd"/>

<DirectiveDescription id="5" source="nd">

<IntentionalVagueness id="19" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="5" source="nd"/>

<DirectiveValue id="5" source="nd"/>

<DirectiveType id="5" source="nd"/>

</Directive>

<Reason id="14" source="nd"/>

<EvidenceQuality id="10" source="nd">

<EvidenceQualityDescription id="10" source="nd"/>

<Disagreement id="10" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="10" source="nd">

<RecommendationStrengthCode id="10" source="nd"/>

</RecommendationStrength>

<Flexibility id="10" source="nd"/>

<Logic id="10" source="nd"/>

<Cost id="10" source="nd"/>

<Linkage id="10" source="nd"/>

<Reference id="10" source="nd"/>

<Certainty id="10" source="nd"/>

<Goal id="10" source="nd"/>

</Imperative>

<RecommendationNotes id="5" source="nd"/>

</Recommendation>

<Recommendation id="6" source="inferred">7 - First Line Treatments: Behavioral Therapies<StatementOfFact id="6" source="nd"/>

<Conditional id="6" source="inferred">Behavioral therapies may be combined with anti-muscarinic therapies.<BenefitHarmAssessment id="11" source="nd"/>

<DecisionVariable id="8" source="inferred">OAB<Value id="8" source="inferred">true</Value>

<DecisionVariableCode id="8" source="nd"/>

<DecisionVariableDescription id="8" source="nd">

<IntentionalVagueness id="20" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="8" source="nd">

<Sensitivity id="8" source="nd"/>

<Specificity id="8" source="nd"/>

<PredictiveValue id="8" source="nd"/>

</TestParameter>

<DecisionVariableCost id="8" source="nd"/>

</DecisionVariable>

<Action id="8" source="inferred">behavioral therapies may be combined with anti-muscarinic therapies.<ActionActor id="8" source="inferred">clinicians</ActionActor>

<ActionCode codeset="" id="8" source="nd"/>

<ActionVerb id="8" source="inferred">combine</ActionVerb>

<ActionDeonticTerm id="8" source="inferred">may</ActionDeonticTerm>

<ActionVerbComplement id="8" source="inferred">behavioral therapies and anti-muscarinic therapies.</ActionVerbComplement>

<ActionBenefit id="8" source="nd"/>

<ActionRiskHarm id="8" source="nd"/>

<ActionDescription id="8" source="nd">

<IntentionalVagueness id="21" source="nd"/>

</ActionDescription>

<ActionCost id="8" source="nd"/>

<ActionValue id="8" source="nd"/>

<ActionType id="8" source="nd"/>

</Action>

<Reason id="21" source="inferred">Behavioral and drug therapies are often used in combination in clinical practice to optimize patient symptom control and QoL. A limited literature indicates that initiating behavioral and drug therapy simultaneously may improve outcomes, including frequency, voided volume, incontinence and symptom distress. In patients who are not adequately improved on behavioral or drug therapy alone, there also is evidence that continuing the initial therapy and adding the alternate therapy using a stepped approach can produce additional benefit. Evidence strength is Grade C because of the limited evidence base consisting of relatively few trials, small sample sizes, and limited follow-up durations.</Reason>

<EvidenceQuality id="11" source="inferred">Grade C; Benefits outweigh risks/burdens<EvidenceQualityDescription id="11" source="nd"/>

<Disagreement id="11" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="11" source="inferred">Recommendation<RecommendationStrengthCode id="11" source="nd"/>

</RecommendationStrength>

<Flexibility id="11" source="nd"/>

<Logic id="11" source="inferred">If &#13;

OAB is [true] &#13;

Then &#13;

behavioral therapies may be combined with anti-muscarinic therapies.</Logic>

<Cost id="11" source="nd"/>

<Linkage id="11" source="nd"/>

<Reference id="11" source="nd"/>

<Certainty id="11" source="nd"/>

<Goal id="11" source="nd"/>

</Conditional>

<Imperative id="6" source="nd">

<BenefitHarmAssessment id="12" source="nd"/>

<Scope id="6" source="nd">

<ScopeCode id="6" source="nd"/>

</Scope>

<Directive id="6" source="nd">

<DirectiveActor id="6" source="nd"/>

<DirectiveCode id="6" source="nd"/>

<DirectiveVerb id="6" source="nd"/>

<DirectiveDeonticTerm id="6" source="nd"/>

<DirectiveVerbComplement id="6" source="nd"/>

<DirectiveBenefit id="6" source="nd"/>

<DirectiveRiskHarm id="6" source="nd"/>

<DirectiveDescription id="6" source="nd">

<IntentionalVagueness id="22" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="6" source="nd"/>

<DirectiveValue id="6" source="nd"/>

<DirectiveType id="6" source="nd"/>

</Directive>

<Reason id="22" source="nd"/>

<EvidenceQuality id="12" source="nd">

<EvidenceQualityDescription id="12" source="nd"/>

<Disagreement id="12" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="12" source="nd">

<RecommendationStrengthCode id="12" source="nd"/>

</RecommendationStrength>

<Flexibility id="12" source="nd"/>

<Logic id="12" source="nd"/>

<Cost id="12" source="nd"/>

<Linkage id="12" source="nd"/>

<Reference id="12" source="nd"/>

<Certainty id="12" source="nd"/>

<Goal id="12" source="nd"/>

</Imperative>

<RecommendationNotes id="6" source="nd"/>

</Recommendation>

<Recommendation id="8" source="inferred">8 - Second-Line Treatments: Anti-Muscarinics<StatementOfFact id="8" source="nd"/>

<Conditional id="8" source="inferred">Clinicians should offer oral anti-muscarinics, including darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine or trospium (listed in alphabetical order; no hierarchy is implied) as second-line therapy.<BenefitHarmAssessment id="15" source="nd"/>

<DecisionVariable id="10" source="inferred">OAB<Value id="10" source="inferred">true</Value>

<DecisionVariableCode codeset="" id="10" source="nd"/>

<DecisionVariableDescription id="10" source="nd">

<IntentionalVagueness id="26" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="10" source="nd">

<Sensitivity id="10" source="nd"/>

<Specificity id="10" source="nd"/>

<PredictiveValue id="10" source="nd"/>

</TestParameter>

<DecisionVariableCost id="10" source="nd"/>

</DecisionVariable>

<Action id="10" source="inferred">Clinicians should offer oral anti-muscarinics, including darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine or trospium (listed in alphabetical order; no hierarchy is implied) as second-line therapy.<ActionActor id="10" source="inferred">clinicians</ActionActor>

<ActionCode codeset="" id="10" source="nd"/>

<ActionVerb id="10" source="inferred">offer</ActionVerb>

<ActionDeonticTerm id="10" source="inferred">should</ActionDeonticTerm>

<ActionVerbComplement id="10" source="inferred">Clinicians should offer oral anti-muscarinics, including darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine or trospium (listed in alphabetical order; no hierarchy is implied) as second-line therapy.</ActionVerbComplement>

<ActionBenefit id="10" source="nd"/>

<ActionRiskHarm id="10" source="inferred">oral anti-muscarinics can commonly have non-life-threatening side effects such as dry mouth, constipation, dry or itchy eyes, blurred vision, dyspepsia, UTI, urinary retention and impaired cognitive function. Rarely, life-threatening side effects such as arrhythmias have been reported.</ActionRiskHarm>

<ActionRiskHarm id="36" source="inferred">The Panel interpreted the oxybutynin and tolterodine data to indicate that the probability that a patient will experience dry mouth and/or constipation appears to be higher overall with the administration of oxybutynin compared to tolterodine.</ActionRiskHarm>

<ActionDescription id="10" source="inferred">Due to the similar efficacy observed for all oral anti-muscarinic medications, the choice of medication for a particular patient depends on the patient’s history of anti-muscarinic use, information regarding adverse events experienced in the past, the impact on the patient of adverse events, patient preferences, comorbidities, use of other medications and the availability of and resources to acquire specific medications. In addition, although there was no evidence of differential efficacy across medications, both qualitative analysis and meta-analysis of all randomized trial arms revealed different adverse event profiles for dry mouth and constipation. This information may be relevant if a patient is particularly sensitive to one of these adverse events.<IntentionalVagueness id="27" source="nd"/>

</ActionDescription>

<ActionCost id="10" source="nd"/>

<ActionValue id="10" source="nd"/>

<ActionType id="10" source="nd"/>

</Action>

<Reason id="25" source="inferred">The choice of oral anti-muscarinics as second-line therapy reflects the fact that these medications reduce symptoms but also can commonly have non-life-threatening side effects such as dry mouth, constipation, dry or itchy eyes, blurred vision, dyspepsia, UTI, urinary retention and impaired cognitive function. Rarely, life-threatening side effects such as arrhythmias have been reported. An extensive review of the randomized trials that evaluated pharmacologic therapies for OAB (including trials with placebo control groups as well as trials with active treatment comparison groups) revealed no compelling evidence for differential efficacy across medications. This finding is consistent with the conclusions of several published systematic reviews. Evidence strength was Grade B because most trials were of moderate quality and follow-up durations were relatively short (i.e., 12 weeks).</Reason>

<EvidenceQuality id="15" source="inferred">Grade B; Benefits outweigh risks/burdens<EvidenceQualityDescription id="15" source="nd"/>

<Disagreement id="15" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="15" source="inferred">Standard<RecommendationStrengthCode id="15" source="nd"/>

</RecommendationStrength>

<Flexibility id="15" source="inferred"/>

<Logic id="15" source="inferred">If &#13;

OAB is [true] &#13;

Then &#13;

Clinicians should offer oral anti-muscarinics, including darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine or trospium (listed in alphabetical order; no hierarchy is implied) as second-line therapy.</Logic>

<Cost id="15" source="nd"/>

<Linkage id="15" source="nd"/>

<Reference id="15" source="nd"/>

<Certainty id="15" source="nd"/>

<Goal id="15" source="nd"/>

</Conditional>

<Imperative id="8" source="nd">

<BenefitHarmAssessment id="16" source="nd"/>

<Scope id="8" source="nd">

<ScopeCode id="8" source="nd"/>

</Scope>

<Directive id="8" source="nd">

<DirectiveActor id="8" source="nd"/>

<DirectiveCode id="8" source="nd"/>

<DirectiveVerb id="8" source="nd"/>

<DirectiveDeonticTerm id="8" source="nd"/>

<DirectiveVerbComplement id="8" source="nd"/>

<DirectiveBenefit id="8" source="nd"/>

<DirectiveRiskHarm id="8" source="nd"/>

<DirectiveDescription id="8" source="nd">

<IntentionalVagueness id="28" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="8" source="nd"/>

<DirectiveValue id="8" source="nd"/>

<DirectiveType id="8" source="nd"/>

</Directive>

<Reason id="26" source="nd"/>

<EvidenceQuality id="16" source="nd">

<EvidenceQualityDescription id="16" source="nd"/>

<Disagreement id="16" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="16" source="nd">

<RecommendationStrengthCode id="16" source="nd"/>

</RecommendationStrength>

<Flexibility id="16" source="nd"/>

<Logic id="16" source="nd"/>

<Cost id="16" source="nd"/>

<Linkage id="16" source="nd"/>

<Reference id="16" source="nd"/>

<Certainty id="16" source="nd"/>

<Goal id="16" source="nd"/>

</Imperative>

<RecommendationNotes id="8" source="nd"/>

</Recommendation>

<Recommendation id="7" source="inferred">9 - Second-Line Treatments: Anti-Muscarinics<StatementOfFact id="7" source="nd"/>

<Conditional id="7" source="inferred">If an immediate release (IR) and an extended release (ER) formulation are available, then ER formulations should preferentially be prescribed over IR formulations because of lower rates of dry mouth.<BenefitHarmAssessment id="13" source="nd"/>

<DecisionVariable id="9" source="inferred">OAB<Value id="9" source="inferred">true</Value>

<DecisionVariableCode id="9" source="nd"/>

<DecisionVariableDescription id="9" source="nd">

<IntentionalVagueness id="23" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="9" source="nd">

<Sensitivity id="9" source="nd"/>

<Specificity id="9" source="nd"/>

<PredictiveValue id="9" source="nd"/>

</TestParameter>

<DecisionVariableCost id="9" source="nd"/>

</DecisionVariable>

<DecisionVariable id="11" source="inferred">prescribing an anti-muscarinic<Value id="11" source="inferred">true</Value>

<DecisionVariableCode id="11" source="nd"/>

<DecisionVariableDescription id="11" source="nd">

<IntentionalVagueness id="34" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="11" source="nd">

<Sensitivity id="11" source="nd"/>

<Specificity id="11" source="nd"/>

<PredictiveValue id="11" source="nd"/>

</TestParameter>

<DecisionVariableCost id="11" source="nd"/>

</DecisionVariable>

<DecisionVariable id="13" source="inferred">an extended release (ER) formulation is available<Value id="13" source="inferred">true</Value>

<DecisionVariableCode id="13" source="nd"/>

<DecisionVariableDescription id="13" source="nd">

<IntentionalVagueness id="36" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="13" source="nd">

<Sensitivity id="13" source="nd"/>

<Specificity id="13" source="nd"/>

<PredictiveValue id="13" source="nd"/>

</TestParameter>

<DecisionVariableCost id="13" source="nd"/>

</DecisionVariable>

<DecisionVariable id="12" source="inferred">an immediate release (IR) formulation is available<Value id="12" source="inferred">true</Value>

<DecisionVariableCode id="12" source="nd"/>

<DecisionVariableDescription id="12" source="nd">

<IntentionalVagueness id="35" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="12" source="nd">

<Sensitivity id="12" source="nd"/>

<Specificity id="12" source="nd"/>

<PredictiveValue id="12" source="nd"/>

</TestParameter>

<DecisionVariableCost id="12" source="nd"/>

</DecisionVariable>

<Action id="9" source="inferred">ER formulations should preferentially be prescribed over IR formulations because of lower rates of dry mouth.<ActionActor id="9" source="inferred">clinicians</ActionActor>

<ActionCode codeset="" id="9" source="nd"/>

<ActionVerb id="9" source="inferred">prescribe</ActionVerb>

<ActionDeonticTerm id="9" source="inferred">should</ActionDeonticTerm>

<ActionVerbComplement id="9" source="inferred">ER formulations over IR formulations</ActionVerbComplement>

<ActionBenefit id="9" source="inferred">lower rates of dry mouth</ActionBenefit>

<ActionRiskHarm id="9" source="nd"/>

<ActionDescription id="9" source="inferred">The decision to prescribe an IR vs. an ER formulation should be made in the context of the patient’s prior experience with anti-muscarinics and the availability of medications, including insurer constraints, in order to minimize patient burden. Insurer constraints may be such that a patient may need to be prescribed an IR formulation and either have inadequate symptom control or have intolerable side effects prior to obtaining approval to be prescribed an ER formulation. The Panel notes that if a patient has good symptom control and tolerable side effects on an IR formulation, then there is no need to change to an ER formulation.<IntentionalVagueness id="24" source="nd"/>

</ActionDescription>

<ActionCost id="9" source="nd"/>

<ActionValue id="9" source="nd"/>

<ActionType id="9" source="nd"/>

</Action>

<Reason id="30" source="inferred">A meta-analysis of adverse events indicated that the ER formulations of oxybutynin and tolterodine resulted in statistically significantly fewer patient reports of dry mouth than the IR formulations of both medications. Within each medication, there was no relationship with dose. There were insufficient trospium trial arms to meta-analyze the IR vs. ER formulations; however, a similar pattern was evident.</Reason>

<Reason id="29" source="inferred">Because OAB is a chronic condition and treatment with anti-muscarinics generally would be required long-term, optimizing medication tolerability is critical to obtaining patient compliance. Adverse drug events, particularly dry mouth, are the major reasons that patients fail to comply with anti-muscarinic therapy; thus choosing the formulation with the lowest likelihood of adverse events may improve compliance. In addition, compliance with a once-daily treatment has been shown to be greater than with medications that are taken more than once a day.</Reason>

<EvidenceQuality id="13" source="inferred">Grade B; Benefits outweigh risks/burdens<EvidenceQualityDescription id="13" source="nd"/>

<Disagreement id="13" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="13" source="inferred">Standard<RecommendationStrengthCode id="13" source="nd"/>

</RecommendationStrength>

<Flexibility id="13" source="nd"/>

<Logic id="13" source="inferred">If &#13;

OAB is [true] &#13;

AND&#13;

prescribing an anti-muscarinic is [true] &#13;

AND&#13;

an extended release (ER) formulation is available is [true] &#13;

AND&#13;

an immediate release (IR) formulation is available is [true] &#13;

Then &#13;

ER formulations should preferentially be prescribed over IR formulations because of lower rates of dry mouth.</Logic>

<Cost id="13" source="nd"/>

<Linkage id="13" source="nd"/>

<Reference id="13" source="nd"/>

<Certainty id="13" source="nd"/>

<Goal id="13" source="nd"/>

</Conditional>

<Imperative id="7" source="nd">

<BenefitHarmAssessment id="14" source="nd"/>

<Scope id="7" source="nd">

<ScopeCode id="7" source="nd"/>

</Scope>

<Directive id="7" source="nd">

<DirectiveActor id="7" source="nd"/>

<DirectiveCode id="7" source="nd"/>

<DirectiveVerb id="7" source="nd"/>

<DirectiveDeonticTerm id="7" source="nd"/>

<DirectiveVerbComplement id="7" source="nd"/>

<DirectiveBenefit id="7" source="nd"/>

<DirectiveRiskHarm id="7" source="nd"/>

<DirectiveDescription id="7" source="nd">

<IntentionalVagueness id="25" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="7" source="nd"/>

<DirectiveValue id="7" source="nd"/>

<DirectiveType id="7" source="nd"/>

</Directive>

<Reason id="24" source="nd"/>

<EvidenceQuality id="14" source="nd">

<EvidenceQualityDescription id="14" source="nd"/>

<Disagreement id="14" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="14" source="nd">

<RecommendationStrengthCode id="14" source="nd"/>

</RecommendationStrength>

<Flexibility id="14" source="nd"/>

<Logic id="14" source="nd"/>

<Cost id="14" source="nd"/>

<Linkage id="14" source="nd"/>

<Reference id="14" source="nd"/>

<Certainty id="14" source="nd"/>

<Goal id="14" source="nd"/>

</Imperative>

<RecommendationNotes id="7" source="inferred"/>

</Recommendation>

<Recommendation id="9" source="inferred">10 - Second-Line Treatments: Anti-Muscarinics<StatementOfFact id="9" source="nd"/>

<Conditional id="9" source="inferred">Transdermal (TDS) oxybutynin (patch or gel) may be offered.<BenefitHarmAssessment id="17" source="nd"/>

<DecisionVariable id="14" source="inferred">OAB<Value id="14" source="inferred">true</Value>

<DecisionVariableCode id="14" source="nd"/>

<DecisionVariableDescription id="14" source="nd">

<IntentionalVagueness id="37" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="14" source="nd">

<Sensitivity id="14" source="nd"/>

<Specificity id="14" source="nd"/>

<PredictiveValue id="14" source="nd"/>

</TestParameter>

<DecisionVariableCost id="14" source="nd"/>

</DecisionVariable>

<DecisionVariable id="15" source="inferred">history of dry mouth with oral agents<Value id="15" source="inferred">true</Value>

<DecisionVariableCode codeset="" id="15" source="nd"/>

<DecisionVariableDescription id="15" source="nd">

<IntentionalVagueness id="40" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="15" source="nd">

<Sensitivity id="15" source="nd"/>

<Specificity id="15" source="nd"/>

<PredictiveValue id="15" source="nd"/>

</TestParameter>

<DecisionVariableCost id="15" source="nd"/>

</DecisionVariable>

<DecisionVariable id="16" source="inferred">at risk of experiencing dry mouth with oral agents<Value id="16" source="inferred">true</Value>

<DecisionVariableCode id="16" source="nd"/>

<DecisionVariableDescription id="16" source="nd">

<IntentionalVagueness id="41" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="16" source="nd">

<Sensitivity id="16" source="nd"/>

<Specificity id="16" source="nd"/>

<PredictiveValue id="16" source="nd"/>

</TestParameter>

<DecisionVariableCost id="16" source="nd"/>

</DecisionVariable>

<Action id="16" source="inferred">Transdermal oxybutynin (patch or gel) may be offered instead of oral anti-muscarinics<ActionActor id="16" source="inferred">clinicians</ActionActor>

<ActionCode id="16" source="nd"/>

<ActionVerb id="16" source="inferred">offer</ActionVerb>

<ActionDeonticTerm id="16" source="inferred">may</ActionDeonticTerm>

<ActionVerbComplement id="16" source="inferred">Transdermal oxybutynin (patch or gel) instead of oral anti-muscarinics</ActionVerbComplement>

<ActionBenefit id="16" source="nd"/>

<ActionRiskHarm id="16" source="inferred"/>

<ActionDescription id="16" source="nd">

<IntentionalVagueness id="38" source="nd"/>

</ActionDescription>

<ActionCost id="16" source="nd"/>

<ActionValue id="16" source="nd"/>

<ActionType id="16" source="nd"/>

</Action>

<Reason id="31" source="inferred">The Panel interpreted available data to indicate that transdermal oxybutynin (patch and gel) is effective in reducing incontinence episodes, in particular, with dry mouth rates that appear to be less than the meta-analyzed rates of 40.0% for oral oxybutynin ER and 68.0% for oral oxybutynin IR. Because the number of studies evaluating TDS oxybutynin was relatively few with different patient inclusion criteria (i.e., known responders to anti-muscarinic medications in some trials), the body of evidence strength was designated as Grade C.</Reason>

<EvidenceQuality id="17" source="inferred">Grade C; Benefits outweigh risks/burdens<EvidenceQualityDescription id="17" source="nd"/>

<Disagreement id="17" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="17" source="inferred">Recommendation<RecommendationStrengthCode id="17" source="nd"/>

</RecommendationStrength>

<Flexibility id="17" source="nd"/>

<Logic id="17" source="inferred">If &#13;

OAB is [true] &#13;&#13;

AND&#13;&#13;

(history of dry mouth with oral agents is [true] &#13;&#13;

OR&#13;&#13;

at risk of experiencing dry mouth with oral agents is [true] ) &#13;

Then &#13;

Transdermal oxybutynin (patch or gel) may be offered instead of oral anti-muscarinics</Logic>

<Cost id="17" source="nd"/>

<Linkage id="17" source="nd"/>

<Reference id="17" source="nd"/>

<Certainty id="17" source="nd"/>

<Goal id="17" source="nd"/>

</Conditional>

<Imperative id="9" source="nd">

<BenefitHarmAssessment id="18" source="nd"/>

<Scope id="9" source="nd">

<ScopeCode id="9" source="nd"/>

</Scope>

<Directive id="9" source="nd">

<DirectiveActor id="9" source="nd"/>

<DirectiveCode id="9" source="nd"/>

<DirectiveVerb id="9" source="nd"/>

<DirectiveDeonticTerm id="9" source="nd"/>

<DirectiveVerbComplement id="9" source="nd"/>

<DirectiveBenefit id="9" source="nd"/>

<DirectiveRiskHarm id="9" source="nd"/>

<DirectiveDescription id="9" source="nd">

<IntentionalVagueness id="39" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="9" source="nd"/>

<DirectiveValue id="9" source="nd"/>

<DirectiveType id="9" source="nd"/>

</Directive>

<Reason id="32" source="nd"/>

<EvidenceQuality id="18" source="nd">

<EvidenceQualityDescription id="18" source="nd"/>

<Disagreement id="18" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="18" source="nd">

<RecommendationStrengthCode id="18" source="nd"/>

</RecommendationStrength>

<Flexibility id="18" source="nd"/>

<Logic id="18" source="nd"/>

<Cost id="18" source="nd"/>

<Linkage id="18" source="nd"/>

<Reference id="18" source="nd"/>

<Certainty id="18" source="nd"/>

<Goal id="18" source="nd"/>

</Imperative>

<RecommendationNotes id="9" source="nd"/>

</Recommendation>

<Recommendation id="10" source="inferred">11 - Second-Line Treatments: Anti-Muscarinics<StatementOfFact id="10" source="nd"/>

<Conditional id="10" source="inferred">If a patient experiences inadequate symptom control and/or unacceptable adverse drug events with one anti-muscarinic medication, then a dose modification or a different anti-muscarinic medication may be tried.<BenefitHarmAssessment id="19" source="nd"/>

<DecisionVariable id="17" source="inferred">OAB<Value id="17" source="inferred">true</Value>

<DecisionVariableCode id="17" source="nd"/>

<DecisionVariableDescription id="17" source="nd">

<IntentionalVagueness id="42" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="17" source="nd">

<Sensitivity id="17" source="nd"/>

<Specificity id="17" source="nd"/>

<PredictiveValue id="17" source="nd"/>

</TestParameter>

<DecisionVariableCost id="17" source="nd"/>

</DecisionVariable>

<DecisionVariable id="20" source="inferred">taking an anti-muscarinic medication<Value id="20" source="inferred">one</Value>

<DecisionVariableCode id="20" source="nd"/>

<DecisionVariableDescription id="20" source="nd">

<IntentionalVagueness id="47" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="20" source="nd">

<Sensitivity id="20" source="nd"/>

<Specificity id="20" source="nd"/>

<PredictiveValue id="20" source="nd"/>

</TestParameter>

<DecisionVariableCost id="20" source="nd"/>

</DecisionVariable>

<DecisionVariable id="19" source="inferred">inadequate symptom control<Value id="19" source="inferred">true</Value>

<DecisionVariableCode codeset="" id="19" source="nd"/>

<DecisionVariableDescription id="19" source="nd">

<IntentionalVagueness id="46" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="19" source="nd">

<Sensitivity id="19" source="nd"/>

<Specificity id="19" source="nd"/>

<PredictiveValue id="19" source="nd"/>

</TestParameter>

<DecisionVariableCost id="19" source="nd"/>

</DecisionVariable>

<DecisionVariable id="21" source="inferred">unacceptable adverse drug events<Value id="21" source="inferred">true</Value>

<DecisionVariableCode id="21" source="nd"/>

<DecisionVariableDescription id="21" source="nd">

<IntentionalVagueness id="48" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="21" source="nd">

<Sensitivity id="21" source="nd"/>

<Specificity id="21" source="nd"/>

<PredictiveValue id="21" source="nd"/>

</TestParameter>

<DecisionVariableCost id="21" source="nd"/>

</DecisionVariable>

<Action id="17" source="inferred">modify dose of current anti-muscarinic medication<ActionActor id="17" source="inferred">clinicians</ActionActor>

<ActionCode id="17" source="nd"/>

<ActionVerb id="17" source="inferred">modify</ActionVerb>

<ActionDeonticTerm id="17" source="inferred">may</ActionDeonticTerm>

<ActionVerbComplement id="17" source="inferred">dosage of current anti-muscarinic medication</ActionVerbComplement>

<ActionBenefit id="17" source="nd"/>

<ActionRiskHarm id="17" source="nd"/>

<ActionDescription id="17" source="nd">

<IntentionalVagueness id="43" source="nd"/>

</ActionDescription>

<ActionCost id="17" source="nd"/>

<ActionValue id="17" source="nd"/>

<ActionType id="17" source="nd"/>

</Action>

<Action id="18" source="inferred">prescribe a different anti-muscarinic medication<ActionActor id="18" source="inferred">clinicians</ActionActor>

<ActionCode id="18" source="nd"/>

<ActionVerb id="18" source="inferred">prescribe</ActionVerb>

<ActionDeonticTerm id="18" source="inferred">may</ActionDeonticTerm>

<ActionVerbComplement id="18" source="inferred">a different anti-muscarinic medication</ActionVerbComplement>

<ActionBenefit id="18" source="nd"/>

<ActionRiskHarm id="18" source="nd"/>

<ActionDescription id="18" source="nd">

<IntentionalVagueness id="49" source="nd"/>

</ActionDescription>

<ActionCost id="18" source="nd"/>

<ActionValue id="18" source="nd"/>

<ActionType id="18" source="nd"/>

</Action>

<Reason id="33" source="inferred">In the Panel’s experience, patients who experience inadequate symptom control and/or unacceptable adverse drug events with one anti-muscarinic medication may experience better symptom control and/or a more acceptable adverse drug event profile with another anti-muscarinic. In addition, in some patients, dose modification (i.e., reducing dose or reducing dose and combining medication with behavioral techniques) may achieve a better balance between efficacy and adverse drug events. A small literature composed of observational studies supports this experience, particularly when switching from an older medication to a newer medication. Patients who had prior unsatisfactory symptom control and/or unacceptable adverse events with tolterodine or oxybutynin reported better efficacy and/or more acceptable adverse event profiles with fesoterodine solifenacin or darifenacin. Based on the Panel’s clinical experience and this limited literature, the Panel advises that clinicians should not abandon anti-muscarinic therapy if trial of one medication appears to fail or produces an unacceptable adverse event profile. There is no literature that addresses combination therapy of anti-muscarinics with each other or with other classes of medication such as tricyclics to manage non-neurogenic OAB.</Reason>

<EvidenceQuality id="19" source="nd">

<EvidenceQualityDescription id="19" source="nd"/>

<Disagreement id="19" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="19" source="inferred">Clinical Principle<RecommendationStrengthCode id="19" source="nd"/>

</RecommendationStrength>

<Flexibility id="19" source="nd"/>

<Logic id="19" source="inferred">If &#13;

OAB is [true] &#13;

AND&#13;

taking an anti-muscarinic medication is [one] &#13;

AND&#13;

(inadequate symptom control is [true] &#13;

OR&#13;

unacceptable adverse drug events is [true] ) &#13;

Then &#13;

modify dose of current anti-muscarinic medication&#13;

OR&#13;

prescribe a different anti-muscarinic medication</Logic>

<Cost id="19" source="nd"/>

<Linkage id="19" source="nd"/>

<Reference id="19" source="nd"/>

<Certainty id="19" source="nd"/>

<Goal id="19" source="nd"/>

</Conditional>

<Imperative id="10" source="nd">

<BenefitHarmAssessment id="20" source="nd"/>

<Scope id="10" source="nd">

<ScopeCode id="10" source="nd"/>

</Scope>

<Directive id="10" source="nd">

<DirectiveActor id="10" source="nd"/>

<DirectiveCode id="10" source="nd"/>

<DirectiveVerb id="10" source="nd"/>

<DirectiveDeonticTerm id="10" source="nd"/>

<DirectiveVerbComplement id="10" source="nd"/>

<DirectiveBenefit id="10" source="nd"/>

<DirectiveRiskHarm id="10" source="nd"/>

<DirectiveDescription id="10" source="nd">

<IntentionalVagueness id="44" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="10" source="nd"/>

<DirectiveValue id="10" source="nd"/>

<DirectiveType id="10" source="nd"/>

</Directive>

<Reason id="34" source="nd"/>

<EvidenceQuality id="20" source="nd">

<EvidenceQualityDescription id="20" source="nd"/>

<Disagreement id="20" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="20" source="nd">

<RecommendationStrengthCode id="20" source="nd"/>

</RecommendationStrength>

<Flexibility id="20" source="nd"/>

<Logic id="20" source="nd"/>

<Cost id="20" source="nd"/>

<Linkage id="20" source="nd"/>

<Reference id="20" source="nd"/>

<Certainty id="20" source="nd"/>

<Goal id="20" source="nd"/>

</Imperative>

<RecommendationNotes id="10" source="nd"/>

</Recommendation>

<Recommendation id="11" source="inferred">12 - Second-Line Treatments: Anti-Muscarinics<StatementOfFact id="11" source="nd"/>

<Conditional id="11" source="inferred">Clinicians should not use anti-muscarinics in patients with narrow angle glaucoma unless approved by the treating ophthalmologist and should use anti-muscarinics with extreme caution in patients with impaired gastric emptying or a history of urinary retention.<BenefitHarmAssessment id="21" source="nd"/>

<DecisionVariable id="22" source="inferred">OAB<Value id="22" source="inferred">true</Value>

<DecisionVariableCode id="22" source="nd"/>

<DecisionVariableDescription id="22" source="nd">

<IntentionalVagueness id="50" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="22" source="nd">

<Sensitivity id="22" source="nd"/>

<Specificity id="22" source="nd"/>

<PredictiveValue id="22" source="nd"/>

</TestParameter>

<DecisionVariableCost id="22" source="nd"/>

</DecisionVariable>

<DecisionVariable id="24" source="inferred">narrow angle glaucoma<Value id="24" source="inferred">true</Value>

<DecisionVariableCode id="24" source="nd"/>

<DecisionVariableDescription id="24" source="nd">

<IntentionalVagueness id="54" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="24" source="nd">

<Sensitivity id="24" source="nd"/>

<Specificity id="24" source="nd"/>

<PredictiveValue id="24" source="nd"/>

</TestParameter>

<DecisionVariableCost id="24" source="nd"/>

</DecisionVariable>

<DecisionVariable id="23" source="inferred">use of anti-muscarinics approved by treating ophthalmologist<Value id="23" source="inferred">false</Value>

<DecisionVariableCode id="23" source="nd"/>

<DecisionVariableDescription id="23" source="nd">

<IntentionalVagueness id="53" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="23" source="nd">

<Sensitivity id="23" source="nd"/>

<Specificity id="23" source="nd"/>

<PredictiveValue id="23" source="nd"/>

</TestParameter>

<DecisionVariableCost id="23" source="nd"/>

</DecisionVariable>

<Action id="19" source="inferred">do not use anti-muscarinics<ActionActor id="19" source="inferred">clinicians</ActionActor>

<ActionCode id="19" source="nd"/>

<ActionVerb id="19" source="inferred">prescribe</ActionVerb>

<ActionDeonticTerm id="19" source="inferred">should not</ActionDeonticTerm>

<ActionVerbComplement id="19" source="inferred">anti-muscarinics</ActionVerbComplement>

<ActionBenefit id="19" source="nd"/>

<ActionRiskHarm id="19" source="nd"/>

<ActionDescription id="19" source="nd">

<IntentionalVagueness id="51" source="nd"/>

</ActionDescription>

<ActionCost id="19" source="nd"/>

<ActionValue id="19" source="nd"/>

<ActionType id="19" source="nd"/>

</Action>

<Reason id="35" source="nd"/>

<EvidenceQuality id="21" source="nd">

<EvidenceQualityDescription id="21" source="nd"/>

<Disagreement id="21" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="21" source="inferred">Clinical Principle<RecommendationStrengthCode id="21" source="nd"/>

</RecommendationStrength>

<Flexibility id="21" source="nd"/>

<Logic id="21" source="inferred">If &#13;

OAB is [true] &#13;&#13;

AND&#13;&#13;

narrow angle glaucoma is [true] &#13;&#13;

AND&#13;&#13;

use of anti-muscarinics approved by treating ophthalmologist is [false] &#13;

Then &#13;

do not use anti-muscarinics</Logic>

<Cost id="21" source="nd"/>

<Linkage id="21" source="nd"/>

<Reference id="21" source="nd"/>

<Certainty id="21" source="nd"/>

<Goal id="21" source="nd"/>

</Conditional>

<Conditional id="12" source="inferred">Clinicians should not use anti-muscarinics in patients with narrow angle glaucoma unless approved by the treating ophthalmologist and should use anti-muscarinics with extreme caution in patients with impaired gastric emptying or a history of urinary retention.<BenefitHarmAssessment id="23" source="nd"/>

<DecisionVariable id="25" source="inferred">OAB<Value id="25" source="inferred">true</Value>

<DecisionVariableCode id="25" source="nd"/>

<DecisionVariableDescription id="25" source="nd">

<IntentionalVagueness id="55" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="25" source="nd">

<Sensitivity id="25" source="nd"/>

<Specificity id="25" source="nd"/>

<PredictiveValue id="25" source="nd"/>

</TestParameter>

<DecisionVariableCost id="25" source="nd"/>

</DecisionVariable>

<DecisionVariable id="27" source="inferred">impaired gastric emptying<Value id="27" source="inferred">true</Value>

<DecisionVariableCode id="27" source="nd"/>

<DecisionVariableDescription id="27" source="nd">

<IntentionalVagueness id="58" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="27" source="nd">

<Sensitivity id="27" source="nd"/>

<Specificity id="27" source="nd"/>

<PredictiveValue id="27" source="nd"/>

</TestParameter>

<DecisionVariableCost id="27" source="nd"/>

</DecisionVariable>

<DecisionVariable id="26" source="inferred">history of urinary retention<Value id="26" source="inferred">true</Value>

<DecisionVariableCode id="26" source="nd"/>

<DecisionVariableDescription id="26" source="nd">

<IntentionalVagueness id="57" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="26" source="nd">

<Sensitivity id="26" source="nd"/>

<Specificity id="26" source="nd"/>

<PredictiveValue id="26" source="nd"/>

</TestParameter>

<DecisionVariableCost id="26" source="nd"/>

</DecisionVariable>

<Action id="20" source="inferred">use anti-muscarinics with extreme caution<ActionActor id="20" source="inferred">clinicians</ActionActor>

<ActionCode id="20" source="nd"/>

<ActionVerb id="20" source="inferred">prescribe</ActionVerb>

<ActionDeonticTerm id="20" source="inferred">should</ActionDeonticTerm>

<ActionVerbComplement id="20" source="inferred">anti-muscarinics with extreme caution</ActionVerbComplement>

<ActionBenefit id="20" source="nd"/>

<ActionRiskHarm id="20" source="nd"/>

<ActionDescription id="20" source="inferred">If the patient is at risk for or has a history of gastric emptying problems, then the patient should be seen by or receive clearance from a gastroenterologist. If the patient has a history of or is at risk of urinary retention, then urology consultation should be strongly considered. It is useful to obtain a post void residual in any patient the clinician suspects has a higher than normal risk of urinary retention. Anti-muscarinics are also contraindicated in patients using solid oral forms of potassium chloride, as the reduced gastric emptying potentially caused by the anti-muscarinics may increase the potassium absorption of these agents. If these patients can be switched to alternative forms of potassium chloride, then anti-muscarinic therapy may be possible with caution. In weighing the risks of anti-muscarinic therapy in high-risk patients, it is important to remember that OAB may compromise quality of life, but it is not a life-threatening condition. Clinicians, therefore, should exercise extreme caution in using treatments that may present life-threatening risks.<IntentionalVagueness id="56" source="nd"/>

</ActionDescription>

<ActionCost id="20" source="nd"/>

<ActionValue id="20" source="nd"/>

<ActionType id="20" source="nd"/>

</Action>

<Reason id="37" source="nd"/>

<EvidenceQuality id="23" source="nd">

<EvidenceQualityDescription id="23" source="nd"/>

<Disagreement id="23" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="23" source="inferred">Clinical Principle<RecommendationStrengthCode id="23" source="nd"/>

</RecommendationStrength>

<Flexibility id="23" source="nd"/>

<Logic id="23" source="inferred">If &#13;

OAB is [true] &#13;&#13;

AND&#13;&#13;

(impaired gastric emptying is [true] &#13;&#13;

OR&#13;&#13;

history of urinary retention is [true] ) &#13;

Then &#13;

use anti-muscarinics with extreme caution</Logic>

<Cost id="23" source="nd"/>

<Linkage id="23" source="nd"/>

<Reference id="23" source="nd"/>

<Certainty id="23" source="nd"/>

<Goal id="23" source="nd"/>

</Conditional>

<Imperative id="11" source="nd">

<BenefitHarmAssessment id="22" source="nd"/>

<Scope id="11" source="nd">

<ScopeCode id="11" source="nd"/>

</Scope>

<Directive id="11" source="nd">

<DirectiveActor id="11" source="nd"/>

<DirectiveCode id="11" source="nd"/>

<DirectiveVerb id="11" source="nd"/>

<DirectiveDeonticTerm id="11" source="nd"/>

<DirectiveVerbComplement id="11" source="nd"/>

<DirectiveBenefit id="11" source="nd"/>

<DirectiveRiskHarm id="11" source="nd"/>

<DirectiveDescription id="11" source="nd">

<IntentionalVagueness id="52" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="11" source="nd"/>

<DirectiveValue id="11" source="nd"/>

<DirectiveType id="11" source="nd"/>

</Directive>

<Reason id="36" source="nd"/>

<EvidenceQuality id="22" source="nd">

<EvidenceQualityDescription id="22" source="nd"/>

<Disagreement id="22" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="22" source="nd">

<RecommendationStrengthCode id="22" source="nd"/>

</RecommendationStrength>

<Flexibility id="22" source="nd"/>

<Logic id="22" source="nd"/>

<Cost id="22" source="nd"/>

<Linkage id="22" source="nd"/>

<Reference id="22" source="nd"/>

<Certainty id="22" source="nd"/>

<Goal id="22" source="nd"/>

</Imperative>

<RecommendationNotes id="11" source="nd"/>

</Recommendation>

<Recommendation id="12" source="inferred">13 - Second-Line Treatments: Anti-Muscarinics<StatementOfFact id="12" source="nd"/>

<Conditional id="13" source="inferred">Clinicians should manage constipation and dry mouth before abandoning effective anti-muscarinic therapy. Management may include bowel management, fluid management, dose modification or alternative anti-muscarinics.<BenefitHarmAssessment id="24" source="nd"/>

<DecisionVariable id="28" source="inferred">OAB<Value id="28" source="inferred">true</Value>

<DecisionVariableCode id="28" source="nd"/>

<DecisionVariableDescription id="28" source="nd">

<IntentionalVagueness id="59" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="28" source="nd">

<Sensitivity id="28" source="nd"/>

<Specificity id="28" source="nd"/>

<PredictiveValue id="28" source="nd"/>

</TestParameter>

<DecisionVariableCost id="28" source="nd"/>

</DecisionVariable>

<DecisionVariable id="31" source="inferred">effective anti-muscarinic therapy<Value id="31" source="inferred">true</Value>

<DecisionVariableCode id="31" source="nd"/>

<DecisionVariableDescription id="31" source="nd">

<IntentionalVagueness id="65" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="31" source="nd">

<Sensitivity id="31" source="nd"/>

<Specificity id="31" source="nd"/>

<PredictiveValue id="31" source="nd"/>

</TestParameter>

<DecisionVariableCost id="31" source="nd"/>

</DecisionVariable>

<DecisionVariable id="29" source="inferred">patient considering discontinuation<Value id="29" source="inferred">true</Value>

<DecisionVariableCode id="29" source="nd"/>

<DecisionVariableDescription id="29" source="nd">

<IntentionalVagueness id="62" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="29" source="nd">

<Sensitivity id="29" source="nd"/>

<Specificity id="29" source="nd"/>

<PredictiveValue id="29" source="nd"/>

</TestParameter>

<DecisionVariableCost id="29" source="nd"/>

</DecisionVariable>

<Action id="21" source="inferred">manage constipation and dry mouth before abandoning effective anti-muscarinic therapy<ActionActor id="21" source="inferred">clinicians</ActionActor>

<ActionCode id="21" source="nd"/>

<ActionVerb id="21" source="inferred">manage</ActionVerb>

<ActionDeonticTerm id="21" source="inferred">should</ActionDeonticTerm>

<ActionVerbComplement id="21" source="inferred">manage constipation and dry mouth before abandoning effective anti-muscarinic therapy</ActionVerbComplement>

<ActionBenefit id="21" source="nd"/>

<ActionRiskHarm id="21" source="nd"/>

<ActionDescription id="23" source="inferred">Management may include bowel management, fluid management, dose modification or alternative anti-muscarinics.<IntentionalVagueness id="66" source="nd"/>

</ActionDescription>

<ActionDescription id="24" source="inferred">Even before initiating anti-muscarinic therapy, patients should be educated about the possible effects of medication on bowel function and the roles of adequate dietary fiber and fluid, psyllium-based fiber supplements, regular exercise and normal bowel habits. Preparing for dry mouth might include advice on oral lubricants, avoiding mouthwashes with alcohol, taking small sips of water, sucking on sugar-free hard candies and chewing sugar-free gum. When dosing options are available, dose reduction can provide relief from side-effects while retaining some therapeutic effects. In older patients who may metabolize drugs differently, it is often advisable to start with a minimal dose and then increase it if it is tolerated well. With multiple drugs available for OAB, trying alternate anti-muscarinics may identify a medication that the patient can more easily tolerate.<IntentionalVagueness id="67" source="nd"/>

</ActionDescription>

<ActionCost id="21" source="nd"/>

<ActionValue id="21" source="nd"/>

<ActionType id="21" source="nd"/>

</Action>

<Reason id="38" source="inferred">One of the main limitations of anti-muscarinic therapy is that the majority of patients discontinue after a few weeks or months. Although there may be several factors involved in this decision, side effects are commonly cited as the reason for discontinuation. One way clinicians can help patients benefit from anti-muscarinic therapy is to proactively monitor for and manage common side-effects.</Reason>

<EvidenceQuality id="24" source="nd">

<EvidenceQualityDescription id="24" source="nd"/>

<Disagreement id="24" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="24" source="inferred">Clinical Principle<RecommendationStrengthCode id="24" source="nd"/>

</RecommendationStrength>

<Flexibility id="24" source="nd"/>

<Logic id="24" source="inferred">If &#13;

OAB is [true] &#13;&#13;

AND&#13;&#13;

effective anti-muscarinic therapy is [true] &#13;&#13;

AND&#13;&#13;

patient considering discontinuation is [true] &#13;

Then &#13;

manage constipation and dry mouth before abandoning effective anti-muscarinic therapy</Logic>

<Cost id="24" source="nd"/>

<Linkage id="24" source="nd"/>

<Reference id="24" source="nd"/>

<Certainty id="24" source="nd"/>

<Goal id="24" source="nd"/>

</Conditional>

<Imperative id="12" source="nd">

<BenefitHarmAssessment id="25" source="nd"/>

<Scope id="12" source="nd">

<ScopeCode id="12" source="nd"/>

</Scope>

<Directive id="12" source="nd">

<DirectiveActor id="12" source="nd"/>

<DirectiveCode id="12" source="nd"/>

<DirectiveVerb id="12" source="nd"/>

<DirectiveDeonticTerm id="12" source="nd"/>

<DirectiveVerbComplement id="12" source="nd"/>

<DirectiveBenefit id="12" source="nd"/>

<DirectiveRiskHarm id="12" source="nd"/>

<DirectiveDescription id="12" source="nd">

<IntentionalVagueness id="61" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="12" source="nd"/>

<DirectiveValue id="12" source="nd"/>

<DirectiveType id="12" source="nd"/>

</Directive>

<Reason id="39" source="nd"/>

<EvidenceQuality id="25" source="nd">

<EvidenceQualityDescription id="25" source="nd"/>

<Disagreement id="25" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="25" source="nd">

<RecommendationStrengthCode id="25" source="nd"/>

</RecommendationStrength>

<Flexibility id="25" source="nd"/>

<Logic id="25" source="nd"/>

<Cost id="25" source="nd"/>

<Linkage id="25" source="nd"/>

<Reference id="25" source="nd"/>

<Certainty id="25" source="nd"/>

<Goal id="25" source="nd"/>

</Imperative>

<RecommendationNotes id="12" source="nd"/>

</Recommendation>

<Recommendation id="13" source="inferred">14 - Second-Line Treatments: Anti-Muscarinics<StatementOfFact id="13" source="nd"/>

<Conditional id="14" source="inferred">Clinicians must use caution in prescribing anti-muscarinics in patients who are using other medications with anti-cholinergic properties.<BenefitHarmAssessment id="26" source="nd"/>

<DecisionVariable id="32" source="inferred">OAB<Value id="32" source="inferred">true</Value>

<DecisionVariableCode id="32" source="nd"/>

<DecisionVariableDescription id="32" source="nd">

<IntentionalVagueness id="68" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="32" source="nd">

<Sensitivity id="32" source="nd"/>

<Specificity id="32" source="nd"/>

<PredictiveValue id="32" source="nd"/>

</TestParameter>

<DecisionVariableCost id="32" source="nd"/>

</DecisionVariable>

<DecisionVariable id="33" source="inferred">use of medications with anti-cholinergic properties<Value id="33" source="inferred">true</Value>

<DecisionVariableCode id="33" source="nd"/>

<DecisionVariableDescription id="33" source="inferred">These medications include tricyclic antidepressants, those used in the treatment of Parkinsonism and other extra-pyramidal diseases and of Alzheimer’s disease, and include benzotropine, biperiden HCl, galantamine, rivastigmine and trihexyphenidyl HCl. Certain anti-nausea medications and those with atropine-like properties, such as trimethaphan, methscopolamine bromide and ipratropium, may also potentiate these side effects. Providers also should exercise caution in patients who are prescribed acetycholinesterase inhibitors such as donepezil. This list is not intended to be exhaustive; prescribers should be aware of precautions and contraindications for these medications.<IntentionalVagueness id="71" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="33" source="nd">

<Sensitivity id="33" source="nd"/>

<Specificity id="33" source="nd"/>

<PredictiveValue id="33" source="nd"/>

</TestParameter>

<DecisionVariableCost id="33" source="nd"/>

</DecisionVariable>

<Action id="23" source="inferred">use caution in prescribing anti-muscarinics<ActionActor id="23" source="inferred">clinicians</ActionActor>

<ActionCode id="23" source="nd"/>

<ActionVerb id="23" source="inferred">use caution in prescribing</ActionVerb>

<ActionDeonticTerm id="23" source="inferred">must</ActionDeonticTerm>

<ActionVerbComplement id="23" source="inferred">anti-muscarinics</ActionVerbComplement>

<ActionBenefit id="23" source="nd"/>

<ActionRiskHarm id="23" source="nd"/>

<ActionDescription id="25" source="inferred">Providers also should exercise caution in patients who are prescribed acetycholinesterase inhibitors such as donepezil. This list is not intended to be exhaustive; prescribers should be aware of precautions and contraindications for these medications.<IntentionalVagueness id="69" source="nd"/>

</ActionDescription>

<ActionCost id="23" source="nd"/>

<ActionValue id="23" source="nd"/>

<ActionType id="23" source="nd"/>

</Action>

<Reason id="40" source="inferred">The concurrent use of other medications with anti-cholinergic activity may potentiate the side effects of the anti-muscarinic class of OAB medications.</Reason>

<EvidenceQuality id="26" source="nd">

<EvidenceQualityDescription id="26" source="nd"/>

<Disagreement id="26" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="26" source="inferred">Expert Opinion<RecommendationStrengthCode id="26" source="nd"/>

</RecommendationStrength>

<Flexibility id="26" source="nd"/>

<Logic id="26" source="inferred">If &#13;

OAB is [true] &#13;&#13;

AND&#13;&#13;

use of medications with anti-cholinergic properties is [true] &#13;

Then &#13;

use caution in prescribing anti-muscarinics</Logic>

<Cost id="26" source="nd"/>

<Linkage id="26" source="nd"/>

<Reference id="26" source="nd"/>

<Certainty id="26" source="nd"/>

<Goal id="26" source="nd"/>

</Conditional>

<Imperative id="13" source="nd">

<BenefitHarmAssessment id="27" source="nd"/>

<Scope id="13" source="nd">

<ScopeCode id="13" source="nd"/>

</Scope>

<Directive id="13" source="nd">

<DirectiveActor id="13" source="nd"/>

<DirectiveCode id="13" source="nd"/>

<DirectiveVerb id="13" source="nd"/>

<DirectiveDeonticTerm id="13" source="nd"/>

<DirectiveVerbComplement id="13" source="nd"/>

<DirectiveBenefit id="13" source="nd"/>

<DirectiveRiskHarm id="13" source="nd"/>

<DirectiveDescription id="13" source="nd">

<IntentionalVagueness id="70" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="13" source="nd"/>

<DirectiveValue id="13" source="nd"/>

<DirectiveType id="13" source="nd"/>

</Directive>

<Reason id="41" source="nd"/>

<EvidenceQuality id="27" source="nd">

<EvidenceQualityDescription id="27" source="nd"/>

<Disagreement id="27" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="27" source="nd">

<RecommendationStrengthCode id="27" source="nd"/>

</RecommendationStrength>

<Flexibility id="27" source="nd"/>

<Logic id="27" source="nd"/>

<Cost id="27" source="nd"/>

<Linkage id="27" source="nd"/>

<Reference id="27" source="nd"/>

<Certainty id="27" source="nd"/>

<Goal id="27" source="nd"/>

</Imperative>

<RecommendationNotes id="13" source="nd"/>

</Recommendation>

<Recommendation id="14" source="inferred">15 - Second-Line Treatments: Anti-Muscarinics<StatementOfFact id="14" source="nd"/>

<Conditional id="15" source="inferred">Clinicians should use caution in prescribing anti-muscarinics in the frail OAB patient.<BenefitHarmAssessment id="28" source="nd"/>

<DecisionVariable id="34" source="inferred">OAB<Value id="34" source="inferred">true</Value>

<DecisionVariableCode id="34" source="nd"/>

<DecisionVariableDescription id="34" source="nd">

<IntentionalVagueness id="72" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="34" source="nd">

<Sensitivity id="34" source="nd"/>

<Specificity id="34" source="nd"/>

<PredictiveValue id="34" source="nd"/>

</TestParameter>

<DecisionVariableCost id="34" source="nd"/>

</DecisionVariable>

<DecisionVariable id="35" source="inferred">frail<Value id="35" source="inferred">true</Value>

<DecisionVariableCode id="35" source="nd"/>

<DecisionVariableDescription id="35" source="inferred">patients with mobility deficits (i.e., require support to walk, have slow gait speed, have difficulty rising from sitting to standing without assistance), weight loss and weakness without medical cause and who may have cognitive deficits<IntentionalVagueness id="75" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="35" source="nd">

<Sensitivity id="35" source="nd"/>

<Specificity id="35" source="nd"/>

<PredictiveValue id="35" source="nd"/>

</TestParameter>

<DecisionVariableCost id="35" source="nd"/>

</DecisionVariable>

<Action id="24" source="inferred">Clinicians should use caution in prescribing anti-muscarinics<ActionActor id="24" source="inferred">clinicians</ActionActor>

<ActionCode id="24" source="nd"/>

<ActionVerb id="24" source="inferred">use caution</ActionVerb>

<ActionDeonticTerm id="24" source="inferred">should</ActionDeonticTerm>

<ActionVerbComplement id="24" source="inferred">in prescribing anti-muscarinics</ActionVerbComplement>

<ActionBenefit id="24" source="nd"/>

<ActionRiskHarm id="24" source="nd"/>

<ActionDescription id="26" source="inferred">Clinicians should begin with the lowest possible dose and increase doses slowly while carefully assessing for the balance between symptom control and adverse events. The use of transdermal anti-muscarinics should be monitored to ensure that the skin where the medication is applied remains intact.<IntentionalVagueness id="73" source="nd"/>

</ActionDescription>

<ActionDescription id="51" source="inferred">In dementia patients, anti-muscarinics should be used with extreme caution or may be contraindicated entirely depending on the level of cognitive impairment.<IntentionalVagueness id="127" source="nd"/>

</ActionDescription>

<ActionCost id="24" source="nd"/>

<ActionValue id="24" source="nd"/>

<ActionType id="24" source="nd"/>

</Action>

<Reason id="42" source="inferred">In frail patients, defined as patients with mobility deficits (i.e., require support to walk, have slow gait speed, have difficulty rising from sitting to standing without assistance), weight loss and weakness without medical cause and who may have cognitive deficits (PR 37, 98, 315), the use of OAB medications may have a lower therapeutic index and a higher adverse drug event profile. OAB medication studies generally are not conducted in the frail elderly, resulting in a lack of data in this group. In the Panel’s experience, however, adverse drug events in addition to the typically reported events of dry mouth and constipation may occur, including impaired thermoregulation that can cause dangerous core temperature elevation.</Reason>

<Reason id="44" source="inferred">Cognitive deficits, particularly memory difficulties, have been reported in response to anti-muscarinics, and clinical experience suggests that elderly patients may be particularly prone to these adverse effects. There is some suggestion that the newer agents (e.g., darifenacin) are less likely to produce cognitive deficits in elderly patients than are the older agents, but the literature is limited and the two-week drug administration period in these studies is not long enough to yield definitive conclusions. Kay notes, however, that patients may not recognize that memory deterioration has occurred, making it essential for the clinician, family members and caregivers to monitor for these effects. In addition, polypharmacy is common in community dwelling patients who are frail, placing them at higher risk for adverse drug events, including impaired cognition. In dementia patients, anti-muscarinics should be used with extreme caution or may be contraindicated entirely depending on the level of cognitive impairment. The clinician should consider these possibilities in prescribing anti-muscarinics to frail patients and reassess the balance between benefits and risks/burdens with the patient, caregiver and/or family on a regular basis and/or when functioning appears to change. In patients who cannot tolerate anti-muscarinics or for whom these medications are not appropriate, behavioral strategies that include prompted voiding and fluid management may be helpful.</Reason>

<EvidenceQuality id="28" source="nd">

<EvidenceQualityDescription id="28" source="nd"/>

<Disagreement id="28" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="28" source="inferred">Clinical Principle<RecommendationStrengthCode id="28" source="nd"/>

</RecommendationStrength>

<Flexibility id="28" source="nd"/>

<Logic id="28" source="inferred">If &#13;

OAB is [true] &#13;&#13;

AND&#13;&#13;

frail is [true] &#13;

Then &#13;

Clinicians should use caution in prescribing anti-muscarinics</Logic>

<Cost id="28" source="nd"/>

<Linkage id="28" source="nd"/>

<Reference id="28" source="nd"/>

<Certainty id="28" source="nd"/>

<Goal id="28" source="nd"/>

</Conditional>

<Imperative id="14" source="nd">

<BenefitHarmAssessment id="29" source="nd"/>

<Scope id="14" source="nd">

<ScopeCode id="14" source="nd"/>

</Scope>

<Directive id="14" source="nd">

<DirectiveActor id="14" source="nd"/>

<DirectiveCode id="14" source="nd"/>

<DirectiveVerb id="14" source="nd"/>

<DirectiveDeonticTerm id="14" source="nd"/>

<DirectiveVerbComplement id="14" source="nd"/>

<DirectiveBenefit id="14" source="nd"/>

<DirectiveRiskHarm id="14" source="nd"/>

<DirectiveDescription id="14" source="nd">

<IntentionalVagueness id="74" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="14" source="nd"/>

<DirectiveValue id="14" source="nd"/>

<DirectiveType id="14" source="nd"/>

</Directive>

<Reason id="43" source="nd"/>

<EvidenceQuality id="29" source="nd">

<EvidenceQualityDescription id="29" source="nd"/>

<Disagreement id="29" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="29" source="nd">

<RecommendationStrengthCode id="29" source="nd"/>

</RecommendationStrength>

<Flexibility id="29" source="nd"/>

<Logic id="29" source="nd"/>

<Cost id="29" source="nd"/>

<Linkage id="29" source="nd"/>

<Reference id="29" source="nd"/>

<Certainty id="29" source="nd"/>

<Goal id="29" source="nd"/>

</Imperative>

<RecommendationNotes id="14" source="nd"/>

</Recommendation>

<Recommendation id="15" source="inferred">16 - Second-Line Treatments: Anti-Muscarinics<StatementOfFact id="15" source="nd"/>

<Conditional id="16" source="inferred">Patients who are refractory to behavioral and medical therapy should be evaluated by an appropriate specialist if they desire additional therapy.<BenefitHarmAssessment id="30" source="nd"/>

<DecisionVariable id="36" source="inferred">refractory OAB<Value id="36" source="inferred">true</Value>

<DecisionVariableCode id="36" source="nd"/>

<DecisionVariableDescription id="36" source="inferred">The Panel defines the refractory patient as the patient who has failed a trial of symptom-appropriate behavioral therapy of sufficient length to evaluate potential efficacy and who has failed a trial of at least one anti-muscarinic medication administered for 6 to 12 weeks. Failure of an anti-muscarinic medication may include lack of efficacy and/or inability to tolerate adverse drug effects. The Panel notes that this definition is a minimum definition; individual clinicians and patients may decide that it is in the best interests of the patient to persevere with behavioral and/or anti-muscarinic therapy for longer periods, to combine behavioral and anti-muscarinic therapies to achieve better efficacy, or to try alternate anti-muscarinics before judging that a patient is refractory.<IntentionalVagueness id="76" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="36" source="nd">

<Sensitivity id="36" source="nd"/>

<Specificity id="36" source="nd"/>

<PredictiveValue id="36" source="nd"/>

</TestParameter>

<DecisionVariableCost id="36" source="nd"/>

</DecisionVariable>

<DecisionVariable id="39" source="inferred">desire additional therapy<Value id="39" source="inferred">true</Value>

<DecisionVariableCode id="39" source="nd"/>

<DecisionVariableDescription id="39" source="nd">

<IntentionalVagueness id="81" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="39" source="nd">

<Sensitivity id="39" source="nd"/>

<Specificity id="39" source="nd"/>

<PredictiveValue id="39" source="nd"/>

</TestParameter>

<DecisionVariableCost id="39" source="nd"/>

</DecisionVariable>

<Action id="25" source="inferred">patients should be evaluated by an appropriate specialist<ActionActor id="25" source="inferred">patients</ActionActor>

<ActionCode id="25" source="nd"/>

<ActionVerb id="25" source="inferred">be evaluated by</ActionVerb>

<ActionDeonticTerm id="25" source="inferred">should</ActionDeonticTerm>

<ActionVerbComplement id="25" source="inferred">an appropriate specialist</ActionVerbComplement>

<ActionBenefit id="25" source="nd"/>

<ActionRiskHarm id="25" source="nd"/>

<ActionDescription id="27" source="inferred">Behavioral therapies present no risks to patients and anti-muscarinics present risks that cease when the medication is stopped. The remaining treatment levels present increasing risks to patients that must be balanced with potential efficacy. Before a patient is exposed to these therapies, a comprehensive evaluation should be conducted to ensure that the patient’s symptoms are attributable to OAB and not to some other disease process that requires other kinds of treatment and the patient’s desire for further treatment should be ascertained.<IntentionalVagueness id="77" source="nd"/>

</ActionDescription>

<ActionCost id="25" source="nd"/>

<ActionValue id="25" source="nd"/>

<ActionType id="25" source="nd"/>

</Action>

<Reason id="45" source="inferred">Behavioral therapies present no risks to patients and anti-muscarinics present risks that cease when the medication is stopped. The remaining treatment levels present increasing risks to patients that must be balanced with potential efficacy.</Reason>

<EvidenceQuality id="30" source="nd">

<EvidenceQualityDescription id="30" source="nd"/>

<Disagreement id="30" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="30" source="inferred">Expert Opinion<RecommendationStrengthCode id="30" source="nd"/>

</RecommendationStrength>

<Flexibility id="30" source="nd"/>

<Logic id="30" source="inferred">If &#13;

refractory OAB is [true] &#13;&#13;

AND&#13;&#13;

desire additional therapy is [true] &#13;

Then &#13;

patients should be evaluated by an appropriate specialist</Logic>

<Cost id="30" source="nd"/>

<Linkage id="30" source="nd"/>

<Reference id="30" source="nd"/>

<Certainty id="30" source="nd"/>

<Goal id="30" source="nd"/>

</Conditional>

<Imperative id="15" source="nd">

<BenefitHarmAssessment id="31" source="nd"/>

<Scope id="15" source="nd">

<ScopeCode id="15" source="nd"/>

</Scope>

<Directive id="15" source="nd">

<DirectiveActor id="15" source="nd"/>

<DirectiveCode id="15" source="nd"/>

<DirectiveVerb id="15" source="nd"/>

<DirectiveDeonticTerm id="15" source="nd"/>

<DirectiveVerbComplement id="15" source="nd"/>

<DirectiveBenefit id="15" source="nd"/>

<DirectiveRiskHarm id="15" source="nd"/>

<DirectiveDescription id="15" source="nd">

<IntentionalVagueness id="78" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="15" source="nd"/>

<DirectiveValue id="15" source="nd"/>

<DirectiveType id="15" source="nd"/>

</Directive>

<Reason id="46" source="nd"/>

<EvidenceQuality id="31" source="nd">

<EvidenceQualityDescription id="31" source="nd"/>

<Disagreement id="31" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="31" source="nd">

<RecommendationStrengthCode id="31" source="nd"/>

</RecommendationStrength>

<Flexibility id="31" source="nd"/>

<Logic id="31" source="nd"/>

<Cost id="31" source="nd"/>

<Linkage id="31" source="nd"/>

<Reference id="31" source="nd"/>

<Certainty id="31" source="nd"/>

<Goal id="31" source="nd"/>

</Imperative>

<RecommendationNotes id="15" source="nd"/>

</Recommendation>

<Recommendation id="16" source="inferred">17 - FDA-Approved Neuromodulation Therapies<StatementOfFact id="16" source="nd"/>

<Conditional id="17" source="inferred">Clinicians may offer sacral neuromodulation (SNS) as third-line treatment in a carefully selected patient population characterized by severe refractory OAB symptoms or patients who are not candidates for second-line therapy and are willing to undergo a surgical procedure.<BenefitHarmAssessment id="32" source="inferred">Given the negative effects on quality of life associated with severe incontinence and frequency, the Panel judged that benefits of SNS in the appropriate patient outweighed the risks/burdens and notes that patients should be carefully counseled regarding the risks/burdens. Evidence strength is Grade C because of the predominance of observational designs, the small sample sizes, the limited number of unique patient groups (i.e., there are multiple reports on the same patient groups followed over time) and limited information regarding the protocols used by patients to maintain symptom control.</BenefitHarmAssessment>

<DecisionVariable id="40" source="inferred">severe refractory OAB symptoms<Value id="40" source="inferred">true</Value>

<DecisionVariableCode id="40" source="nd"/>

<DecisionVariableDescription id="40" source="inferred">

<IntentionalVagueness id="82" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="40" source="nd">

<Sensitivity id="40" source="nd"/>

<Specificity id="40" source="nd"/>

<PredictiveValue id="40" source="nd"/>

</TestParameter>

<DecisionVariableCost id="40" source="nd"/>

</DecisionVariable>

<DecisionVariable id="42" source="inferred">candidate for second-line therapy<Value id="42" source="inferred">false</Value>

<DecisionVariableCode id="42" source="nd"/>

<DecisionVariableDescription id="42" source="nd">

<IntentionalVagueness id="86" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="42" source="nd">

<Sensitivity id="42" source="nd"/>

<Specificity id="42" source="nd"/>

<PredictiveValue id="42" source="nd"/>

</TestParameter>

<DecisionVariableCost id="42" source="nd"/>

</DecisionVariable>

<DecisionVariable id="41" source="inferred">willing to undergo a surgical procedure<Value id="41" source="inferred">true</Value>

<DecisionVariableCode id="41" source="nd"/>

<DecisionVariableDescription id="41" source="nd">

<IntentionalVagueness id="85" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="41" source="nd">

<Sensitivity id="41" source="nd"/>

<Specificity id="41" source="nd"/>

<PredictiveValue id="41" source="nd"/>

</TestParameter>

<DecisionVariableCost id="41" source="nd"/>

</DecisionVariable>

<Action id="26" source="inferred">Clinicians may offer sacral neuromodulation (SNS) as third-line treatment<ActionActor id="26" source="inferred">clinicians</ActionActor>

<ActionCode id="26" source="nd"/>

<ActionVerb id="26" source="inferred">offer</ActionVerb>

<ActionDeonticTerm id="26" source="inferred">may</ActionDeonticTerm>

<ActionVerbComplement id="26" source="inferred">sacral neuromodulation (SNS) as third-line treatment</ActionVerbComplement>

<ActionBenefit id="26" source="nd"/>

<ActionRiskHarm id="26" source="inferred">In contrast to PTNS studies (see discussion under Guideline Statement 18), SNS studies reported frequent adverse events, including pain at the stimulator site (3.3 to 19.8% of patients), pain at the lead site (4.5 to 19.1% of patients), lead migration (2.2 to 8.6% of patients), infection/irritation (2.2 to 14.30% of patients), electric shock (5.5 to 7.9% of patients) and need for surgical revision (6.25 to 39.5% of patients). In most studies, the need for surgical revision occurred in greater than 30% of patients. There is some evidence that newer, less invasive surgical procedures and tined devices may be associated with fewer adverse events. Leong (2011) reported that although 90% of patients reported satisfaction with SNS, 56% reported adverse events, particularly pain at the stimulator site and when the stimulator was turned on and daily life limitations, such as difficulty passing through airport metal detectors and inability to undergo magnetic resonance imaging (MRI).</ActionRiskHarm>

<ActionDescription id="28" source="inferred">The Panel notes that patients should be counseled that the device requires periodic replacement in a planned surgical procedure and that the length of time between replacements depends on device settings. Patients also must be willing to comply with the treatment protocol because treatment effects typically are only maintained as long as the therapy is maintained and have the cognitive capacity to use the remote control to optimize device function. In addition, patients must accept that the use of diagnostic MRIs is contraindicated in individuals with the device implanted.<IntentionalVagueness id="83" source="nd"/>

</ActionDescription>

<ActionCost id="26" source="nd"/>

<ActionValue id="26" source="nd"/>

<ActionType id="26" source="nd"/>

</Action>

<Reason id="47" source="inferred">The Panel interpreted available data to indicate that in carefully selected patients, SNS is an appropriate therapy that can have durable treatment effects but in the context of frequent and moderately severe adverse events, including the need for additional surgeries.</Reason>

<EvidenceQuality id="32" source="inferred">Grade C; Benefits outweigh risks/burdens<EvidenceQualityDescription id="32" source="nd"/>

<Disagreement id="32" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="32" source="inferred">Recommendation<RecommendationStrengthCode id="32" source="nd"/>

</RecommendationStrength>

<Flexibility id="32" source="nd"/>

<Logic id="32" source="inferred">If &#13;

(severe refractory OAB symptoms is [true] &#13;&#13;

OR&#13;&#13;

candidate for second-line therapy is [false] ) &#13;&#13;

AND&#13;&#13;

willing to undergo a surgical procedure is [true] &#13;

Then &#13;

Clinicians may offer sacral neuromodulation (SNS) as third-line treatment</Logic>

<Cost id="32" source="nd"/>

<Linkage id="32" source="nd"/>

<Reference id="32" source="nd"/>

<Certainty id="32" source="nd"/>

<Goal id="32" source="nd"/>

</Conditional>

<Imperative id="16" source="nd">

<BenefitHarmAssessment id="33" source="nd"/>

<Scope id="16" source="nd">

<ScopeCode id="16" source="nd"/>

</Scope>

<Directive id="16" source="nd">

<DirectiveActor id="16" source="nd"/>

<DirectiveCode id="16" source="nd"/>

<DirectiveVerb id="16" source="nd"/>

<DirectiveDeonticTerm id="16" source="nd"/>

<DirectiveVerbComplement id="16" source="nd"/>

<DirectiveBenefit id="16" source="nd"/>

<DirectiveRiskHarm id="16" source="nd"/>

<DirectiveDescription id="16" source="nd">

<IntentionalVagueness id="84" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="16" source="nd"/>

<DirectiveValue id="16" source="nd"/>

<DirectiveType id="16" source="nd"/>

</Directive>

<Reason id="48" source="nd"/>

<EvidenceQuality id="33" source="nd">

<EvidenceQualityDescription id="33" source="nd"/>

<Disagreement id="33" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="33" source="nd">

<RecommendationStrengthCode id="33" source="nd"/>

</RecommendationStrength>

<Flexibility id="33" source="nd"/>

<Logic id="33" source="nd"/>

<Cost id="33" source="nd"/>

<Linkage id="33" source="nd"/>

<Reference id="33" source="nd"/>

<Certainty id="33" source="nd"/>

<Goal id="33" source="nd"/>

</Imperative>

<RecommendationNotes id="16" source="nd"/>

</Recommendation>

<Recommendation id="17" source="inferred">18 - FDA-Approved Neuromodulation Therapies<StatementOfFact id="17" source="nd"/>

<Conditional id="18" source="inferred">Clinicians may offer peripheral tibial nerve stimulation (PTNS) as third-line treatment in a carefully selected patient population.<BenefitHarmAssessment id="34" source="nd"/>

<DecisionVariable id="43" source="inferred">moderately severe baseline incontinence<Value id="43" source="inferred">true</Value>

<DecisionVariableCode id="43" source="nd"/>

<DecisionVariableDescription id="45" source="inferred">

<IntentionalVagueness id="89" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="43" source="nd">

<Sensitivity id="43" source="nd"/>

<Specificity id="43" source="nd"/>

<PredictiveValue id="43" source="nd"/>

</TestParameter>

<DecisionVariableCost id="43" source="nd"/>

</DecisionVariable>

<DecisionVariable id="54" source="inferred">moderately severe baseline frequency<Value id="54" source="inferred">true</Value>

<DecisionVariableCode id="55" source="nd"/>

<DecisionVariableDescription id="56" source="nd">

<IntentionalVagueness id="128" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="54" source="nd">

<Sensitivity id="54" source="nd"/>

<Specificity id="54" source="nd"/>

<PredictiveValue id="54" source="nd"/>

</TestParameter>

<DecisionVariableCost id="54" source="nd"/>

</DecisionVariable>

<DecisionVariable id="55" source="inferred">willingness to comply with the PTNS protocol<Value id="55" source="inferred">true</Value>

<DecisionVariableCode id="56" source="nd"/>

<DecisionVariableDescription id="57" source="nd">

<IntentionalVagueness id="129" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="55" source="nd">

<Sensitivity id="55" source="nd"/>

<Specificity id="55" source="nd"/>

<PredictiveValue id="55" source="nd"/>

</TestParameter>

<DecisionVariableCost id="55" source="nd"/>

</DecisionVariable>

<DecisionVariable id="56" source="inferred">resources to make frequent office visits in order to obtain treatment<Value id="56" source="inferred">true</Value>

<DecisionVariableCode id="57" source="nd"/>

<DecisionVariableDescription id="58" source="nd">

<IntentionalVagueness id="130" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="56" source="nd">

<Sensitivity id="56" source="nd"/>

<Specificity id="56" source="nd"/>

<PredictiveValue id="56" source="nd"/>

</TestParameter>

<DecisionVariableCost id="56" source="nd"/>

</DecisionVariable>

<Action id="27" source="inferred">Clinicians may offer peripheral tibial nerve stimulation (PTNS) as third-line treatment<ActionActor id="27" source="inferred">clinicians</ActionActor>

<ActionCode id="27" source="nd"/>

<ActionVerb id="27" source="inferred">offer</ActionVerb>

<ActionDeonticTerm id="27" source="inferred">may</ActionDeonticTerm>

<ActionVerbComplement id="27" source="inferred">peripheral tibial nerve stimulation (PTNS) as third-line treatment</ActionVerbComplement>

<ActionBenefit id="27" source="nd"/>

<ActionRiskHarm id="27" source="nd"/>

<ActionDescription id="29" source="nd">

<IntentionalVagueness id="90" source="nd"/>

</ActionDescription>

<ActionCost id="27" source="nd"/>

<ActionValue id="27" source="nd"/>

<ActionType id="27" source="nd"/>

</Action>

<Reason id="52" source="inferred">The Panel interpreted available data to indicate that PTNS can benefit a carefully selected group of patients characterized by moderately severe baseline incontinence and frequency and willingness to comply with the PTNS protocol. Patients must also have the resources to make frequent office visits in order to obtain treatment because treatment effects dissipate once treatment ceases. As a group, the PTNS studies constitute Grade C evidence because of the predominant observational designs, varying patient inclusion criteria and short follow-up durations for most studies.</Reason>

<EvidenceQuality id="34" source="inferred">Grade C; Balance between benefits and risks/burdens uncertain<EvidenceQualityDescription id="34" source="nd"/>

<Disagreement id="34" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="34" source="inferred">Option<RecommendationStrengthCode id="34" source="nd"/>

</RecommendationStrength>

<Flexibility id="34" source="nd"/>

<Logic id="34" source="inferred">If &#13;

moderately severe baseline incontinence is [true] &#13;&#13;

AND&#13;&#13;

moderately severe baseline frequency is [true] &#13;&#13;

AND&#13;&#13;

willingness to comply with the PTNS protocol is [true] &#13;&#13;

AND&#13;&#13;

resources to make frequent office visits in order to obtain treatment is [true] &#13;

Then &#13;

Clinicians may offer peripheral tibial nerve stimulation (PTNS) as third-line treatment</Logic>

<Cost id="34" source="nd"/>

<Linkage id="34" source="nd"/>

<Reference id="34" source="nd"/>

<Certainty id="34" source="nd"/>

<Goal id="34" source="nd"/>

</Conditional>

<Imperative id="17" source="nd">

<BenefitHarmAssessment id="35" source="nd"/>

<Scope id="17" source="nd">

<ScopeCode id="17" source="nd"/>

</Scope>

<Directive id="17" source="nd">

<DirectiveActor id="17" source="nd"/>

<DirectiveCode id="17" source="nd"/>

<DirectiveVerb id="17" source="nd"/>

<DirectiveDeonticTerm id="17" source="nd"/>

<DirectiveVerbComplement id="17" source="nd"/>

<DirectiveBenefit id="17" source="nd"/>

<DirectiveRiskHarm id="17" source="nd"/>

<DirectiveDescription id="17" source="nd">

<IntentionalVagueness id="91" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="17" source="nd"/>

<DirectiveValue id="17" source="nd"/>

<DirectiveType id="17" source="nd"/>

</Directive>

<Reason id="51" source="nd"/>

<EvidenceQuality id="35" source="nd">

<EvidenceQualityDescription id="35" source="nd"/>

<Disagreement id="35" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="35" source="nd">

<RecommendationStrengthCode id="35" source="nd"/>

</RecommendationStrength>

<Flexibility id="35" source="nd"/>

<Logic id="35" source="nd"/>

<Cost id="35" source="nd"/>

<Linkage id="35" source="nd"/>

<Reference id="35" source="nd"/>

<Certainty id="35" source="nd"/>

<Goal id="35" source="nd"/>

</Imperative>

<RecommendationNotes id="17" source="nd"/>

</Recommendation>

<Recommendation id="18" source="inferred">19 - Non-FDA-Approved: Intradetrusor injection of onabotulinumtoxinA<StatementOfFact id="18" source="nd"/>

<Conditional id="19" source="inferred">Clinicians may offer intradetrusor onabotulinumtoxinA as third-line treatment in the carefully-selected and thoroughly-counseled patient who has been refractory to first- and second-line OAB treatments. The patient must be able and willing to return for frequent post-void residual evaluation and able and willing to perform self-catheterization if necessary.<BenefitHarmAssessment id="36" source="nd"/>

<DecisionVariable id="44" source="inferred">refractory to first-line OAB treatments<Value id="44" source="inferred">true</Value>

<DecisionVariableCode id="44" source="nd"/>

<DecisionVariableDescription id="46" source="nd">

<IntentionalVagueness id="92" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="44" source="nd">

<Sensitivity id="44" source="nd"/>

<Specificity id="44" source="nd"/>

<PredictiveValue id="44" source="nd"/>

</TestParameter>

<DecisionVariableCost id="44" source="nd"/>

</DecisionVariable>

<DecisionVariable id="58" source="inferred">refractory to second-line OAB treatments<Value id="58" source="inferred">true</Value>

<DecisionVariableCode id="59" source="nd"/>

<DecisionVariableDescription id="60" source="nd">

<IntentionalVagueness id="132" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="58" source="nd">

<Sensitivity id="58" source="nd"/>

<Specificity id="58" source="nd"/>

<PredictiveValue id="58" source="nd"/>

</TestParameter>

<DecisionVariableCost id="58" source="nd"/>

</DecisionVariable>

<DecisionVariable id="57" source="inferred">thoroughly counseled<Value id="57" source="inferred">true</Value>

<DecisionVariableCode id="58" source="nd"/>

<DecisionVariableDescription id="59" source="nd">

<IntentionalVagueness id="131" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="57" source="nd">

<Sensitivity id="57" source="nd"/>

<Specificity id="57" source="nd"/>

<PredictiveValue id="57" source="nd"/>

</TestParameter>

<DecisionVariableCost id="57" source="nd"/>

</DecisionVariable>

<DecisionVariable id="60" source="inferred">able and willing to to return for frequent post-void residual evaluation<Value id="60" source="inferred">true</Value>

<DecisionVariableCode codeset="" id="61" source="nd"/>

<DecisionVariableDescription id="62" source="nd">

<IntentionalVagueness id="134" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="60" source="nd">

<Sensitivity id="60" source="nd"/>

<Specificity id="60" source="nd"/>

<PredictiveValue id="60" source="nd"/>

</TestParameter>

<DecisionVariableCost id="60" source="nd"/>

</DecisionVariable>

<DecisionVariable id="59" source="inferred">able and willing to perform self-catheterization if necessary.<Value id="59" source="inferred">true</Value>

<DecisionVariableCode id="60" source="nd"/>

<DecisionVariableDescription id="61" source="nd">

<IntentionalVagueness id="133" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="59" source="nd">

<Sensitivity id="59" source="nd"/>

<Specificity id="59" source="nd"/>

<PredictiveValue id="59" source="nd"/>

</TestParameter>

<DecisionVariableCost id="59" source="nd"/>

</DecisionVariable>

<Action id="28" source="inferred">Clinicians may offer intradetrusor onabotulinumtoxinA as third-line treatment<ActionActor id="28" source="inferred">clinicians</ActionActor>

<ActionCode codeset="" id="28" source="nd"/>

<ActionVerb id="28" source="inferred">offer</ActionVerb>

<ActionDeonticTerm id="28" source="inferred">may</ActionDeonticTerm>

<ActionVerbComplement id="28" source="inferred">intradetrusor onabotulinumtoxinA as third-line treatment</ActionVerbComplement>

<ActionBenefit id="28" source="nd"/>

<ActionRiskHarm id="28" source="nd"/>

<ActionDescription id="30" source="inferred">Patients considering onabotulinumtoxinA treatment must be counseled regarding the possible need to perform self-catheterization for long periods (or to have a caregiver perform catheterization) and should be willing to accept this possibility. OnabotulinumtoxinA treatment also may require access to a clinician who can measure PVR on a periodic basis if necessary. Further, effects diminish over time for most patients; therefore, patients also should be informed that repeat injections are likely to be necessary to maintain symptom reduction. The Panel also believes that this procedure should be performed by experienced personnel familiar with intravesical injection techniques.<IntentionalVagueness id="93" source="nd"/>

</ActionDescription>

<ActionCost id="28" source="nd"/>

<ActionValue id="28" source="nd"/>

<ActionType id="28" source="nd"/>

</Action>

<Reason id="53" source="inferred">The Panel designated intradetrusor onabotulinumtoxinA treatment as an option because although most studies reported improvements in measured parameters, rates of adverse events that could compromise quality of life or lead to serious illness were extremely high in some trials, making the balance between benefits and risks/burdens unclear. In addition, at the time of this writing, intradetrusor onabotulinumtoxinA is not FDA-approved for treatment of non-neurogenic OAB.</Reason>

<Reason id="56" source="inferred">The Panel interpreted available data to indicate that, although onabotulinumtoxinA injections can improve symptoms, the risk of adverse events that could require secondary intervention is substantial (e.g., an untreated UTI, undiagnosed urinary retention). Evidence strength is Grade C because follow-up durations were short in the best-designed studies (ranging from 4 to 12 weeks for the RCTs), most of the available studies were observational designs without control groups, doses and injection sites varied across studies, adverse event reporting was extremely variable and the total number of patients evaluated in the randomized trials was small (approximately 400).</Reason>

<EvidenceQuality id="36" source="inferred">Grade C; Balance between benefits and risks/burdens uncertain<EvidenceQualityDescription id="36" source="nd"/>

<Disagreement id="36" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="36" source="inferred">Option<RecommendationStrengthCode id="36" source="nd"/>

</RecommendationStrength>

<Flexibility id="36" source="nd"/>

<Logic id="36" source="inferred">If &#13;

refractory to first-line OAB treatments is [true] &#13;&#13;

AND&#13;&#13;

refractory to second-line OAB treatments is [true] &#13;&#13;

AND&#13;&#13;

thoroughly counseled is [true] &#13;&#13;

AND&#13;&#13;

able and willing to to return for frequent post-void residual evaluation is [true] &#13;&#13;

AND&#13;&#13;

able and willing to perform self-catheterization if necessary. is [true] &#13;

Then &#13;

Clinicians may offer intradetrusor onabotulinumtoxinA as third-line treatment</Logic>

<Cost id="36" source="nd"/>

<Linkage id="36" source="nd"/>

<Reference id="36" source="nd"/>

<Certainty id="36" source="nd"/>

<Goal id="36" source="nd"/>

</Conditional>

<Imperative id="18" source="nd">

<BenefitHarmAssessment id="37" source="nd"/>

<Scope id="18" source="nd">

<ScopeCode id="18" source="nd"/>

</Scope>

<Directive id="18" source="nd">

<DirectiveActor id="18" source="nd"/>

<DirectiveCode id="18" source="nd"/>

<DirectiveVerb id="18" source="nd"/>

<DirectiveDeonticTerm id="18" source="nd"/>

<DirectiveVerbComplement id="18" source="nd"/>

<DirectiveBenefit id="18" source="nd"/>

<DirectiveRiskHarm id="18" source="nd"/>

<DirectiveDescription id="18" source="nd">

<IntentionalVagueness id="94" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="18" source="nd"/>

<DirectiveValue id="18" source="nd"/>

<DirectiveType id="18" source="nd"/>

</Directive>

<Reason id="54" source="nd"/>

<EvidenceQuality id="37" source="nd">

<EvidenceQualityDescription id="37" source="nd"/>

<Disagreement id="37" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="37" source="nd">

<RecommendationStrengthCode id="37" source="nd"/>

</RecommendationStrength>

<Flexibility id="37" source="nd"/>

<Logic id="37" source="nd"/>

<Cost id="37" source="nd"/>

<Linkage id="37" source="nd"/>

<Reference id="37" source="nd"/>

<Certainty id="37" source="nd"/>

<Goal id="37" source="nd"/>

</Imperative>

<RecommendationNotes id="18" source="inferred">The available literature on intravesical use of onoabotlinumtoxinA is reviewed below; the Panel focused this treatment Option on injections into the detrusor specifically because most studies assessed this injection location. There is insufficient evidence at present to comment on the relative efficacy of injections into other intravesical locations.</RecommendationNotes>

</Recommendation>

<Recommendation id="19" source="inferred">20 - Additional Treatments<StatementOfFact id="19" source="nd"/>

<Conditional id="21" source="inferred">Indwelling catheters (including transurethral, suprapubic, etc.) are not recommended as a management strategy for OAB because of the adverse risk/benefit balance except as a last resort in selected patients.<BenefitHarmAssessment id="40" source="nd"/>

<DecisionVariable id="49" source="inferred">urinary incontinence has resulted in the development and progression of decubiti<Value id="49" source="inferred">true</Value>

<DecisionVariableCode codeset="" id="49" source="inferred">true</DecisionVariableCode>

<DecisionVariableDescription id="51" source="nd">

<IntentionalVagueness id="102" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="49" source="nd">

<Sensitivity id="49" source="nd"/>

<Specificity id="49" source="nd"/>

<PredictiveValue id="49" source="nd"/>

</TestParameter>

<DecisionVariableCost id="49" source="nd"/>

</DecisionVariable>

<DecisionVariable id="47" source="inferred">urinary incontinence is the predominant disability affecting activities of daily living and therefore may result in institutionalization<Value id="47" source="inferred">true</Value>

<DecisionVariableCode id="47" source="nd"/>

<DecisionVariableDescription id="49" source="nd">

<IntentionalVagueness id="100" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="47" source="nd">

<Sensitivity id="47" source="nd"/>

<Specificity id="47" source="nd"/>

<PredictiveValue id="47" source="nd"/>

</TestParameter>

<DecisionVariableCost id="47" source="nd"/>

</DecisionVariable>

<DecisionVariable id="61" source="inferred">medical management of burdensome OAB is not feasible, effective nor recommended<Value id="61" source="inferred">true</Value>

<DecisionVariableCode id="62" source="nd"/>

<DecisionVariableDescription id="63" source="inferred">as in the patient with severe cognitive deficits or mobility issues<IntentionalVagueness id="135" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="61" source="nd">

<Sensitivity id="61" source="nd"/>

<Specificity id="61" source="nd"/>

<PredictiveValue id="61" source="nd"/>

</TestParameter>

<DecisionVariableCost id="61" source="nd"/>

</DecisionVariable>

<Action id="30" source="inferred">As a last resort, an indwelling catheter may be considered.<ActionActor id="30" source="inferred">clinicians</ActionActor>

<ActionCode codeset="" id="30" source="nd"/>

<ActionVerb id="30" source="inferred">consider</ActionVerb>

<ActionDeonticTerm id="30" source="inferred">may</ActionDeonticTerm>

<ActionVerbComplement id="30" source="inferred">an indwelling catheter (including transurethral, suprapubic, etc.) as a last resort</ActionVerbComplement>

<ActionBenefit id="30" source="nd"/>

<ActionRiskHarm id="30" source="nd"/>

<ActionDescription id="32" source="nd">

<IntentionalVagueness id="99" source="nd"/>

</ActionDescription>

<ActionCost id="30" source="nd"/>

<ActionValue id="30" source="nd"/>

<ActionType id="30" source="nd"/>

</Action>

<Reason id="59" source="inferred">In situations where the medical management of burdensome OAB, as outlined above, is not feasible, effective nor recommended, as in the patient with severe cognitive deficits or mobility issues, then other management options may need to be considered. Management with diapering and absorbent garments is always preferred to indwelling catheterization because of the high risk of indwelling catheter-associated UTIs, urethral erosion/destruction and urolithiasis. Intermittent catheterization may be an option when concomitant incomplete bladder emptying is present leading to overflow incontinence; however, this approach generally requires either patient willingness and ability or significant caregiver support.</Reason>

<EvidenceQuality id="40" source="nd">

<EvidenceQualityDescription id="40" source="nd"/>

<Disagreement id="40" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="40" source="inferred">Expert Opinion<RecommendationStrengthCode id="40" source="nd"/>

</RecommendationStrength>

<Flexibility id="40" source="nd"/>

<Logic id="40" source="inferred">If &#13;

urinary incontinence has resulted in the development and progression of decubiti is [true] &#13;&#13;

OR&#13;&#13;

urinary incontinence is the predominant disability affecting activities of daily living and therefore may result in institutionalization is [true] &#13;&#13;

OR&#13;&#13;

medical management of burdensome OAB is not feasible, effective nor recommended is [true] &#13;

Then &#13;

As a last resort, an indwelling catheter may be considered.</Logic>

<Cost id="40" source="nd"/>

<Linkage id="40" source="nd"/>

<Reference id="40" source="nd"/>

<Certainty id="40" source="nd"/>

<Goal id="40" source="nd"/>

</Conditional>

<Imperative id="19" source="nd">

<BenefitHarmAssessment id="39" source="nd"/>

<Scope id="19" source="nd">

<ScopeCode id="19" source="nd"/>

</Scope>

<Directive id="19" source="nd">

<DirectiveActor id="19" source="nd"/>

<DirectiveCode id="19" source="nd"/>

<DirectiveVerb id="19" source="nd"/>

<DirectiveDeonticTerm id="19" source="nd"/>

<DirectiveVerbComplement id="19" source="nd"/>

<DirectiveBenefit id="19" source="nd"/>

<DirectiveRiskHarm id="19" source="nd"/>

<DirectiveDescription id="19" source="nd">

<IntentionalVagueness id="97" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="19" source="nd"/>

<DirectiveValue id="19" source="nd"/>

<DirectiveType id="19" source="nd"/>

</Directive>

<Reason id="58" source="nd"/>

<EvidenceQuality id="39" source="nd">

<EvidenceQualityDescription id="39" source="nd"/>

<Disagreement id="39" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="39" source="nd">

<RecommendationStrengthCode id="39" source="nd"/>

</RecommendationStrength>

<Flexibility id="39" source="nd"/>

<Logic id="39" source="nd"/>

<Cost id="39" source="nd"/>

<Linkage id="39" source="nd"/>

<Reference id="39" source="nd"/>

<Certainty id="39" source="nd"/>

<Goal id="39" source="nd"/>

</Imperative>

<RecommendationNotes id="19" source="nd"/>

</Recommendation>

<Recommendation id="20" source="inferred">21 - Additional Treatments<StatementOfFact id="20" source="nd"/>

<Conditional id="22" source="inferred">In rare cases, augmentation cystoplasty or urinary diversion for severe, refractory, complicated OAB patients may be considered.<BenefitHarmAssessment id="41" source="nd"/>

<DecisionVariable id="50" source="inferred">severe OAB<Value id="50" source="inferred">true</Value>

<DecisionVariableCode id="50" source="nd"/>

<DecisionVariableDescription id="52" source="nd">

<IntentionalVagueness id="103" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="50" source="nd">

<Sensitivity id="50" source="nd"/>

<Specificity id="50" source="nd"/>

<PredictiveValue id="50" source="nd"/>

</TestParameter>

<DecisionVariableCost id="50" source="nd"/>

</DecisionVariable>

<DecisionVariable id="52" source="inferred">refractory OAB<Value id="52" source="inferred">true</Value>

<DecisionVariableCode id="52" source="nd"/>

<DecisionVariableDescription id="54" source="nd">

<IntentionalVagueness id="107" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="52" source="nd">

<Sensitivity id="52" source="nd"/>

<Specificity id="52" source="nd"/>

<PredictiveValue id="52" source="nd"/>

</TestParameter>

<DecisionVariableCost id="52" source="nd"/>

</DecisionVariable>

<DecisionVariable id="51" source="inferred">complicated OAB<Value id="51" source="inferred">true</Value>

<DecisionVariableCode id="51" source="nd"/>

<DecisionVariableDescription id="53" source="nd">

<IntentionalVagueness id="106" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="51" source="nd">

<Sensitivity id="51" source="nd"/>

<Specificity id="51" source="nd"/>

<PredictiveValue id="51" source="nd"/>

</TestParameter>

<DecisionVariableCost id="51" source="nd"/>

</DecisionVariable>

<Action id="31" source="inferred">In rare cases, augmentation cystoplasty or urinary diversion may be considered.<ActionActor id="31" source="inferred">clinicians</ActionActor>

<ActionCode codeset="" id="31" source="nd"/>

<ActionVerb id="31" source="inferred">consider</ActionVerb>

<ActionDeonticTerm id="31" source="inferred">may</ActionDeonticTerm>

<ActionVerbComplement id="31" source="inferred">augmentation cystoplasty or urinary diversion</ActionVerbComplement>

<ActionBenefit id="31" source="nd"/>

<ActionRiskHarm id="31" source="nd"/>

<ActionDescription id="33" source="nd">

<IntentionalVagueness id="104" source="nd"/>

</ActionDescription>

<ActionCost id="31" source="nd"/>

<ActionValue id="31" source="nd"/>

<ActionType id="31" source="nd"/>

</Action>

<Reason id="60" source="inferred">In general, surgery is not recommended for OAB patients except in extremely rare cases. The vast majority of case series that document the effects of augmentation cystoplasty and diversion focus on neurogenic patients. Little is known regarding the impact of these procedures on non-neurogenic OAB patients and, particularly, on their quality of life. There are substantial risks to these procedures, however, including the likely need for long-term intermittent self-catheterization and the risk of malignancy.199 In the Panel’s judgment, therefore, a surgical approach to OAB treatment is appropriate only in the extremely rare patient.</Reason>

<EvidenceQuality id="41" source="nd">

<EvidenceQualityDescription id="41" source="nd"/>

<Disagreement id="41" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="41" source="nd">

<RecommendationStrengthCode id="41" source="nd"/>

</RecommendationStrength>

<Flexibility id="41" source="nd"/>

<Logic id="41" source="inferred">If &#13;

severe OAB is [true] &#13;&#13;

OR&#13;&#13;

refractory OAB is [true] &#13;&#13;

OR&#13;&#13;

complicated OAB is [true] &#13;

Then &#13;

In rare cases, augmentation cystoplasty or urinary diversion may be considered.</Logic>

<Cost id="41" source="nd"/>

<Linkage id="41" source="nd"/>

<Reference id="41" source="nd"/>

<Certainty id="41" source="nd"/>

<Goal id="41" source="nd"/>

</Conditional>

<Imperative id="20" source="nd">

<BenefitHarmAssessment id="42" source="nd"/>

<Scope id="20" source="nd">

<ScopeCode id="20" source="nd"/>

</Scope>

<Directive id="20" source="nd">

<DirectiveActor id="20" source="nd"/>

<DirectiveCode id="20" source="nd"/>

<DirectiveVerb id="20" source="nd"/>

<DirectiveDeonticTerm id="20" source="nd"/>

<DirectiveVerbComplement id="20" source="nd"/>

<DirectiveBenefit id="20" source="nd"/>

<DirectiveRiskHarm id="20" source="nd"/>

<DirectiveDescription id="20" source="nd">

<IntentionalVagueness id="105" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="20" source="nd"/>

<DirectiveValue id="20" source="nd"/>

<DirectiveType id="20" source="nd"/>

</Directive>

<Reason id="61" source="nd"/>

<EvidenceQuality id="42" source="nd">

<EvidenceQualityDescription id="42" source="nd"/>

<Disagreement id="42" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="42" source="nd">

<RecommendationStrengthCode id="42" source="nd"/>

</RecommendationStrength>

<Flexibility id="42" source="nd"/>

<Logic id="42" source="nd"/>

<Cost id="42" source="nd"/>

<Linkage id="42" source="nd"/>

<Reference id="42" source="nd"/>

<Certainty id="42" source="nd"/>

<Goal id="42" source="nd"/>

</Imperative>

<RecommendationNotes id="20" source="nd"/>

</Recommendation>

<Recommendation id="21" source="inferred">22 - Follow-Up<StatementOfFact id="21" source="nd"/>

<Conditional id="23" source="inferred">The clinician should offer follow up with the patient to assess compliance, efficacy, side effects and possible alternative treatments.<BenefitHarmAssessment id="43" source="nd"/>

<DecisionVariable id="53" source="inferred">OAB<Value id="53" source="inferred">true</Value>

<DecisionVariableCode id="53" source="nd"/>

<DecisionVariableDescription id="55" source="nd">

<IntentionalVagueness id="108" source="nd"/>

</DecisionVariableDescription>

<TestParameter id="53" source="nd">

<Sensitivity id="53" source="nd"/>

<Specificity id="53" source="nd"/>

<PredictiveValue id="53" source="nd"/>

</TestParameter>

<DecisionVariableCost id="53" source="nd"/>

</DecisionVariable>

<Action id="32" source="inferred">The clinician should offer follow up with the patient to assess compliance, efficacy, side effects and possible alternative treatments.<ActionActor id="32" source="inferred">clinicians</ActionActor>

<ActionCode id="32" source="nd"/>

<ActionVerb id="32" source="inferred">offer</ActionVerb>

<ActionDeonticTerm id="32" source="inferred">should</ActionDeonticTerm>

<ActionVerbComplement id="32" source="inferred">follow up to assess compliance, efficacy, side effects and possible alternative treatments.</ActionVerbComplement>

<ActionBenefit id="32" source="nd"/>

<ActionRiskHarm id="32" source="nd"/>

<ActionDescription id="34" source="inferred">The purpose of follow-up is to assess compliance with treatment protocols, query patients regarding symptom improvements and any adverse events and present information about possible alternative treatments to patients who have insufficient symptom improvement and/or intolerable adverse events. There are many ways to measure symptom changes, including voiding diaries with or without frequency-volume charts and patient-rated global response scales for urgency, urgency incontinence, incontinence, frequency and nocturia. In addition, validated OAB-specific instruments may be used to assess the impact of OAB symptoms on quality of life. Ideally, clinicians should obtain baseline measures using the same instruments in order to chart progress. Patients should be encouraged to persist with a particular treatment for four to eight weeks; this time period will identify the majority of responders.<IntentionalVagueness id="109" source="nd"/>

</ActionDescription>

<ActionDescription id="37" source="inferred">Clinicians and any clinical personnel engaged in follow-up should be aware that the various treatment options for OAB have different requirements for efficacy and different adverse event probabilities and severities. For example, the efficacy of some treatments (e.g., behavioral therapies, neuromodulation) depends greatly on treatment compliance, and the efficacy must be balanced against possible adverse events. For other treatments, such as the use of anti-muscarinics, adverse events are common but vary in severity across patients. Patients should be informed about and subsequently queried regarding dry mouth and its severity (i.e., sufficient to impair alimentation), constipation, fecal retention and any possible central nervous system (CNS) effects. Queries of the patient and caregiver regarding CNS effects are particularly important in elderly or frail patients; clinical experience suggests that CNS effects can be severe enough to cause loss of independent living skills in some patients. Non-responders to anti-muscarinics should be tried on at least one other anti-muscarinic and/or dose modification attempted to determine if a better balance between efficacy and adverse events occurs. If adverse events are severe enough to compromise patient quality of life, then strategies to manage specific adverse events, such as ameliorating constipation with appropriate bowel management, should be implemented before abandoning anti-muscarinic treatment.<IntentionalVagueness id="113" source="nd"/>

</ActionDescription>

<ActionDescription id="36" source="inferred">For therapies collectively labeled as neuromodulation, including sacral neuromodulation and peripheral tibial nerve stimulation, pre- and post-therapy measures are essential to assess efficacy. The before-and-after evaluation should include baseline assessment with a voiding diary and assessment of urgency as well as a global response assessment. Adverse events such as pain and collateral stimulation should be assessed, and sacral neuromodulation wound complications should be evaluated.<IntentionalVagueness id="112" source="nd"/>

</ActionDescription>

<ActionDescription id="35" source="inferred">Patients treated with intradetrusor onabotulinumtoxinA should be followed for the possibility of increased PVRs and the need for self-catheterization. Patients who have undergone surgical treatments (e.g., augmentation cystoplasty with or without sling, supravesical diversion) or permanent or semi-permanent catheter placements also should be followed regularly for symptom level, QoL and any complications. Patients who are using incontinence pads, regardless of whether or how they are being treated, should be followed for appropriate skin care and skin integrity.<IntentionalVagueness id="111" source="nd"/>

</ActionDescription>

<ActionCost id="32" source="nd"/>

<ActionValue id="32" source="nd"/>

<ActionType id="32" source="nd"/>

</Action>

<Reason id="62" source="nd"/>

<EvidenceQuality id="43" source="nd">

<EvidenceQualityDescription id="43" source="nd"/>

<Disagreement id="43" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="43" source="inferred">Expert Opinion<RecommendationStrengthCode id="43" source="nd"/>

</RecommendationStrength>

<Flexibility id="43" source="nd"/>

<Logic id="43" source="inferred">If &#13;

OAB is [true] &#13;

Then &#13;

The clinician should offer follow up with the patient to assess compliance, efficacy, side effects and possible alternative treatments.</Logic>

<Cost id="43" source="nd"/>

<Linkage id="43" source="nd"/>

<Reference id="43" source="nd"/>

<Certainty id="43" source="nd"/>

<Goal id="43" source="nd"/>

</Conditional>

<Imperative id="21" source="nd">

<BenefitHarmAssessment id="44" source="nd"/>

<Scope id="21" source="nd">

<ScopeCode id="21" source="nd"/>

</Scope>

<Directive id="21" source="nd">

<DirectiveActor id="21" source="nd"/>

<DirectiveCode id="21" source="nd"/>

<DirectiveVerb id="21" source="nd"/>

<DirectiveDeonticTerm id="21" source="nd"/>

<DirectiveVerbComplement id="21" source="nd"/>

<DirectiveBenefit id="21" source="nd"/>

<DirectiveRiskHarm id="21" source="nd"/>

<DirectiveDescription id="21" source="nd">

<IntentionalVagueness id="110" source="nd"/>

</DirectiveDescription>

<DirectiveCost id="21" source="nd"/>

<DirectiveValue id="21" source="nd"/>

<DirectiveType id="21" source="nd"/>

</Directive>

<Reason id="63" source="nd"/>

<EvidenceQuality id="44" source="nd">

<EvidenceQualityDescription id="44" source="nd"/>

<Disagreement id="44" source="nd"/>

</EvidenceQuality>

<RecommendationStrength id="44" source="nd">

<RecommendationStrengthCode id="44" source="nd"/>

</RecommendationStrength>

<Flexibility id="44" source="nd"/>

<Logic id="44" source="nd"/>

<Cost id="44" source="nd"/>

<Linkage id="44" source="nd"/>

<Reference id="44" source="nd"/>

<Certainty id="44" source="nd"/>

<Goal id="44" source="nd"/>

</Imperative>

<RecommendationNotes id="21" source="nd"/>

</Recommendation>

<Definition id="1" source="inferred">

<Term id="1" source="inferred">OAB<TermMeaning id="1" source="inferred">urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of UTI or other obvious pathology</TermMeaning>

</Term>

<Term id="1" source="inferred">urgency<TermMeaning id="1" source="inferred">the complaint of a sudden, compelling desire to pass urine which is difficult to defer</TermMeaning>

</Term>

<Term id="2" source="inferred">nocturia<TermMeaning id="2" source="inferred">the complaint of interruption of sleep one or

Introduction more times because of the need to void</TermMeaning>

</Term>

<Term id="3" source="inferred">urgency urinary incontinence<TermMeaning id="3" source="inferred">the involuntary leakage of urine, associated with a sudden compelling desire to void.</TermMeaning>

</Term>

</Definition>

<Algorithm id="1" source="nd">

<ActionStep id="1" source="nd"/>

<ConditionalStep id="1" source="nd"/>

<BranchStep id="1" source="nd"/>

<SynchronizationStep id="1" source="nd"/>

</Algorithm>

<ResearchAgenda id="1" source="nd"/>

<BackgroundInformation id="1" source="nd"/>

</KnowledgeComponents>

<Testing id="1" source="nd">

<ExternalReview id="1" source="nd"/>

<PilotTesting id="1" source="nd"/>

<FormalAppraisal id="1" source="nd"/>

</Testing>

<RevisionPlan id="1" source="nd">

<Expiration id="1" source="nd"/>

<ScheduledReview id="1" source="nd"/>

</RevisionPlan>

<ImplementationPlan id="1" source="nd">

<ImplementationStrategy id="1" source="nd"/>

<AnticipatedBarrier id="1" source="nd"/>

<AnticipatedEnabler id="1" source="nd"/>

<PerformanceMeasure id="1" source="nd"/>

</ImplementationPlan>

</GuidelineDocument>